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ABSTRACT 
SALEH ALLABABIDI. Site-Specific (Local) Delivery of Antibiotics from Biodegradable 
GMS Based Implants for the Prevention of Post-Operative Wound Infections. (Under the 
direction ofJAYMIN SHAH, Ph.D.) 
Systemic administration of prophylactic antibiotics has been reported to 
sigirificantly decrease, but not eHminate postoperative infections mainly due to the failure 
in achieving adequate levels of antibiotics at the surgical wound. The local administration 
guarantees the delivery of adequate levels of antibiotics and is therefore advantageous as a 
prophylactic measure. Hence, the overall objective of this study was to develop a glyceryl 
mono stearate (GMS) based biocompatible, bioerodible system to provide short term (1-3 
days) local delivery of antibiotics. GMS based matrices were prepared by direct 
compression. Erosion enhancers were incorporated into the GMS matrix to facilitate the 
bioerosion and bioabsorption of the matrix when implanted in vivo. Cefazolin loaded 
matrices were coated with different GMS mixtures based coating. Combining 4 matrices 
resulted in a sequential release of cefazolin that lasted 2.5 days in vitro. The efficacy and 
pharmacokinetics of cefazolin delivered locally by GMS based implants were evaluated in 
a rat model infected subcutaneously with Staphylococcus aureus, simulating a post-
operative wound infection. The prevention of abscess formation was used as a measure of 
efficacy as compared to a control group, in which rats did not receive any antibiotic. The 
efficacy of the implants was also compared to that of multiple 1M injections (1M group) of 
equal dose of cefazolin. There was no abscess formation in the implant group compared to 
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2.78 % abscess formation in the 1M group and 58.33 % in the control group. The GMS 
implants sustained the release of cefazolin for a period of three days with little fluctuation 
in plasma concentrations. The release of cefazolin from the implants was nearly zero order 
for the entire duration. The bioerosion of the GMS implants was evaluated in an additional 
group of rats. Six weeks post implantation, 16.67 % of the implants had completely 
disappeared and the rest had a weight loss ranging between 20 - 80%, indicating the 
bioerodibility of the GMS implants. Overall, the research was successful in designing a 
delivery system that provided a prolonged delivery of cefazolin for three days, effectively 
prevented a staphylococcus aureus infection, and demonstrated biocompatibility in 
additon to significant bioerosion and biodegradation. 
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DISSERTATION OUTLINE 
This dissertation is composed of three independent research studies. The studies 
are connected by common goals and objectives. Each study is presented as a separate 
investigation and may be read as such. The research is presented in four chapters, each 
with its own introduction and literature references. Each study served an important role in 
achieving the overall objective. The aim of the first chapter is to provide an overall 
introduction to the research and to provide the specific aims of the three research studies. 
CHAPTER I 
INTRODUCTION AND OBJECTIVES 
2 
1. Introduction 
Post-operative wound infections contribute substantially to the morbidity and costs 
associated with surgery. The economical, physical and psychological impact of 
postoperative wound sepsis mandates the use of proper preventive measures to minimize 
infections (1). In the United States, most of the 23 million patients who undergo surgery 
annually receive perioperative antimicrobial prophylaxis. Despite this practice 500,000 -
920,000 surgical wound infections occur annually, accounting for 24% of all nosocomial 
infections (2). 
The use of state of the art aseptic techniques dramaticany reduced, but did not 
eliminate bacterial contamination of the surgical field (3). The administration of 
perioperative antibiotics usuany supplements the aseptic techniques in containing the 
inevitable contamination of the operative wound. The efficacy of prophylactic antibiotics 
has been verified for hundreds of surgical procedures with a wide variety of antibiotics 
when care has been given to provide adequate serum and tissue levels of antibiotics during 
the surgical procedure. Hence, antibiotic administration and aseptic techniques have 
become routine aspects of care in most major surgical procedures. Antibiotics are 
administered prior to the surgical operations in some cases, and in others, a high dose of 
the antibiotic of choice is administered intravenously in order to achieve an effective 
concentration of the antibiotic at the site of the surgery. Surgeons have justified continuing 
postoperative antibiotics for 2 to 3 days in patients who have undergone major surgical 
procedures (4). 
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Penicillins, aminoglycosides and cJindamycin are frequently used as prophylactic 
antibiotics. Cephalosporins, however, are the drugs of choice for the vast majority of 
operative procedures (4), ,with cefazolin being the dominant prophylactic antibiotic in most 
of the surgical operations (4, 5). 
As a prophylactic antibiotic, one gram cefazolin is recommended to be 
administered IV or 1M prior to the start of surgery in order to achieve adequate antibiotic 
levels in the serum and tissues during the initial period of surgery, followed by 0.5 to 1 g 
IV or 1M every 6 to 8 hours for 24 hours postoperatively. Cefazolin may be continued for 
3 to 5 days follo'Wing the surgery, in which the occurrence of an infection is particularly 
devastating (prosthetic arthroplasty) (6). Other prophylactic antibiotics are also 
administered systemically. The systemic administration of some antibiotics such as 
aminoglycosides could lead to side effects due to the systemic exposure to toxic 
concentrations. In addition to being potentially toxic, the systemic administration is 
ineffective when the blood supply to the surgical site is compromised (7). 
The systemic continuous infusion of cefazolin has been demonstrated to provide a 
longer time period above the minimal inhibitory concentration (MIC) for the infecting 
organism in the infected tissues than obtained by the intermittent administration of an 
equivalent dose (8). Therefore, the continuous infusion was reported to be superior to the 
intermittent administration (8). The inefficacy of the intermittent therapy of most of the 
standard antibiotics is due in part to the rapid elimination of the antibiotics from the 
patient's system Therefore, antibiotics are often repeatedly administered in relatively large 
doses. 
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The local administration of antibiotics into the surgical site has been used to supply 
the tissues at risk of infection with higher local concentrations than those obtained with 
systemic administration, while reducing the systemic exposure to potentially toxic 
concentrations of the drug. Initially, antibiotics were directly administered to the surgical 
wound (9 - 11). This practice was hindered by the rapid absorption of the antibiotic from 
the surgical site. To compensate·for the rapid absorption, local infusions (irrigation) were 
introduced and have been reported to be effective in the prevention of wound infections 
(12, 13). However, this practice is cumbersome and requires continuous medical attention. 
With the objective of local delivery, antibiotic releasing systems have been 
developed using non biodegradable polymethylmethacrylate (PMMA) bone cement. In 
1970, Buchholz and Engelbrecht (14) published the first clinical results of using antibiotics 
loaded polymethyJmetbacrylate (PMMA) bone cement as a prophylactic measure against 
deep infections complicating total hip replacement. There have been numerous studies 
reporting the improved efficacy of the local delivery of antibiotics by the PMMA bone 
i' 
cement in the treatment of various bone ,and soft-tissue infections (14 .. 21). Barton and 
Moir (17) have used gentamicin loaded PMMA beads as the only prophylactic measure in 
major head and neck surgery. They reported a significant reduction in infection rate in the 
patients treated with the beads compared to patients who did not receive antibiotic 
treatment and to those who received parenteral antibiotic treatment (16, 17). The use of 
antibiotic loaded beads as the only prophylactic provides the following advantages: 
patients comfort, lack of major complications, and reduction in medical care and hospital 
expenses (16). However, the PMMA bone cement is a non-biodegradable copolymer, thus 
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beads removal operation is required. The removal procedure is painful if performed 
without anesthesia, in addition to the possibility of re-infecting the wound during the bead 
removal operation (16). 
Biodegradable materials such as plaster of paris, bone graft and fibrin clot were 
initially evaluated as carriers for localized delivery of antibiotics (7) but had little success 
due to formulation difficulties such . as the lack of mechanical strength and the 
irreproducibility of the release patterns. Also bone graft and fibrin clot have been found to 
possess antigenic properties. Various types of polymers have been developed as 
biocompatible and biodegradable systems to be used as implants for local delivery of drug, 
these polymers include: poly (a-esters), poly ( aliphatic acids), polyorthoesters, 
polyphosphazenes, polymers based on amino acids, natural materials such as collagen, and 
polysaccharides (22). Dideoxykanamycin B loaded Poly (DL-Iactic acid) and gentamicin-
loaded polyanhydrides devices are some examples of biodegradable delivery systems that 
have been reported to be effective in animal models (23, 24). 
Polyanhydride, PMMA and poly (DL lactic/glycolic acid) based delivery systems 
are often designed to sustain the release of the antibiotics for relatively long periods of 
time (weeks and months) (7, 21, 23, 24). However, this relatively long duration (weeks 
and months) of release is not required for the prevention of post-operative wound 
infections. The administration of antibiotics over the course of several days (3 - 5 days at 
the most) has been proven to be effective as a prophylactic measure in most of the surgical 
operations (1, 4). 
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The advantages of using a biodegradablelbioerodible system for short term (several 
days) delivery of antibiotics in postoperative infections management include: 1) achieving 
high local antibiotic tissue levels while minimizing prolonged elevated serum levels, thus 
improving efficacy and avoiding side effects, 2) avoiding bacterial spread and cross-
contamination from inigationldrainage devices, 3) avoiding the need for the removal of 
the delivery system since it would biodegrade or bioerode after implantation in vivo, 4) 
eliminating the need for the repeated administration of the antibiotic (orally/parenterally), 
and 5) reducing patient care costs as a result of earlier patient mobilization (25). 
The field of biodegradable polymers (poly a-esters, poly-lactic acid, 
polyanhydrides, poly lactic/glycolic acid (PLGA), etc.) has been widely explored, leading 
to new chemical entities which often exhibit little versatility. The new polymers require 
extensive toxicological and compatibility studies in order to obtain the approval of the 
regulatory authorities (FDA) for their use in humans. Only few polymers such as PLG~ 
are accepted for human use due to the lack of pharmacokinetic and toxicological data 
about the synthetic polymers. The process of collecting pharmacokinetic and toxicological 
data is essential for the verification of the safety of the new polymers for h~ use. 
However, this process requires long time and large amounts of money. For the above 
reasons, the field of natural biodegradable materials for drug delivery continues to be an 
active area of research despite the advent of synthetic biodegradable polymers. Natural 
materials are attractive primarily because they are products of living organisms and their 
fate in the body is knOWD.. In addition to that, they are readily available and relatively 
inexpensive. The majority of research in the natural material field has been concentrated 
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on proteins (collagen, gelatin and albumin), polysaccharides (starch, cellulose, inulin, etc.) 
and fatty materials (Mono-, di- and tri-glycerides) (22, 26). 
Glyceryl mono stearate (OMS), a natural monoglyceride, fulfills the desired 
characteristics of materials to be used as biodegradable drug delivery carriers. These 
characteristics of OMS can be summarized as follows (22): 1) OMS is biologically inert, 
thus having minimal effect on the body, 2) GMS has well defined degradation pathways to 
non toxic and easily metabolized products, 3) GMS production process does not produce 
toxic endogenous impurities, and 4) OMS is easy to handle, process and formulate into a 
delivery system such as cylinder or tablet shaped device. 
Glyceryl mono stearate (GMS) is a natural product found in animal fat and 
hydrogenated vegetable oils. It is also a substrate in the human metabolism and 
biosynthesis of lipids. Among its several metabolic pathways, OMS can be used as a 
building block in the biosynthesis of triglyceride or it can be hydrolyzed into glycerol and 
stearic acid. Stearic acid can undergo f3-oxidation to break down to shorter fatty acids or 
it can be used for the biosynthesis of lipids (27). This knowledge about the safe disposition 
of GMS in human body should greatly facilitate the FDA approval of the use of GMS as a 
biocompatible, bioerodible, biodegradable, implantable matrix for the delivery of drugs. 
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2. Objectives 
The overall objective was to develop a biocompatible, bioerodible, implantable 
delivery system based on glyceryl mono stearate (GMS), for the delivery of antibiotics. 
The delivery system was intended to provide short term (1-3 days), site-directed (local) 
delivery of a model antibiotic (cefazolin) for potential use in the prevention of post-
operative wound infections. 
In order to achieve the overall objective, the specific aims of this research were as 
follows: 
1. To evaluate the suitability of OMS for the preparation of an implantable delivery 
system and explore the feasibility of incoIporating antibiotics into this system 
2. To develop a preparation method which minimized drug degradation, was simple and 
produced matrices that exhibited reproducible release and erosion characteristics. 
3. To develop/adapt a suitable in vitro release method which was simple and minimized 
drug degradation after its release from the devices. 
4. To optimize drug release and matrix erosion. 
5. To study and characterize the mechanism and kinetics of drug release from the GMS 
based devices. 
6. To evaluate the effect of drug solubility on the release kinetics and duration from the 
GMS matrices. 
7. To design a GMS based delivery system which is suitable for subcutaneous 
implantation in a rat model. The delivery system is aimed at delivering 180 mg/kg 
cefazolin over a three day period at a zero order release rate. 
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8. To evaluate the in vivo efficacy of cefazolin delivered locally from GMS implants as a 
preventative measure against post-operative wound infections. 
9. To evaluate the phannacokinetics of cefazolin delivered by the GMS implants and 
compare the pharmacokinetic parameters to those of intermittent intramuscular (1M) 
injections of equivalent dose of cefazolin. 
10. To evaluate the in vivo release kinetics of cefazolin from GMS based devices. 
11. To evaluate the biocompatibility and bioerosion of the implants. 
Specific aims 1 - 4 were addressed in the study described in chapter n, in which 
cefazolin was incorporated in GMS based devices. The devices were prepared by 
compression. The compression method did not expose the loaded cefazolin to thermal 
degradation during the preparation steps. The compressed devices exhibited reproducible 
release and erosion characteristics. The in vitro release of cefazolin was conducted by the 
vial method, which was simple and minimized drug degradation during the release study_ 
Erosion enhancers were incorporated into the GMS matrix in order to facilitate the 
erosion of the matrix. In addition to enhancing the erosion of the matrix, the erosion 
enhancers accelerated the drug release rate. Therefore, the composition of the GMS based 
matrix was optimized with regard to the release duration and erosion characteristics. 
Specific aims 5 - 7 were addressed in the study described in chapter ill, in which 
the mechanism and kinetics of cefazolin and ciprofloxacin release were studied. The effect 
of drug solubility, drug load and the geometry of the matrix on the release characteristics 
were determined. An equation for the prediction of the release rate based on drug load and 
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matrix surface area was developed for highly water soluble drug in GMS based matrix. A 
GMS based delivery system for the delivery of cefazolin over a three day period was 
designed and later evaluated in vivo. 
Specific aims 8 - 12 were addressed in the study descn1>ed in chapter IV, in which 
the efficacy and the pharmacokinetics of cefazolin delivered by the GMS implants were 
evaluated in an infection model in Sprague-Dawley rats. The implants provided a three day 
release duration of cefazolin that was effective in totally eradicating the induced infection. 
Six weeks post-implantation, some of the implants completely disappeared and others lost 
20 - 79 % of their weight. This indicated the bioerodibility and biodegradability of our 
GMS based implants. There was no visible irritation or inflammation around the implants 
indicating the biocompatibility of the implants. 
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CHAPTER II 
GL YCERYL MONOSTEARATE AS A BIOERODffiLE DELIVERY SYSTEM FOR 
ANTffiIOTICS: FEASmILITY AND OPTIMIZATION STUDIES 
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Summary 
Antibiotics are used as a prophylactic measure against post-operative wound 
infections. The local delivery of antibiotics has been reported to be more effective than the 
systemic administration of antibiotics. Biodegradable devices are ideal for the local 
delivery of antibiotics at the surgical wound. The research in this area is mainly focused on 
synthetic polymers, which require long time and large sums of money in order to verify 
their safety for human use. However, natural biodegradable materials such as collagen, 
polysaccharides and glycerides continue to be attractive for the use as delivery systems 
primarily because of their known fate in the body in addition to being readily available and 
relatively inexpensive. 
In this research, glyceryl monostearate (GMS) a natural glyceride was investigated 
as a carrier for the delivery of antibiotics. CefazoIin, one of the most commonly used 
prophylactic agents, was used as a model antibiotic. Cefazolin resembles most of the 
antibiotics in their high water solubility andlor their thermal instability_ The GMS devices 
were prepared by the compression method. This method did not expose the loaded 
cefazolin to elevated temperatures, therefore the degradation of cefazolin during the 
preparation process was avoided. The vial release method was used to monitor the release 
of cefazolin from the GMS based devices. In this release method, the release medium was 
frequently replaced by a fresh buffer solution at each sampling time point. The frequent 
replacement of the release medium resulted in the prevention of significant degradation of 
cefazolin after it had been released from the devices. This allowed us to better quantify 
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and characterize the release profile of cefazolin from the devices. Several surfactants and 
hydrophilic agents were investigated as erosion enhancers in order to aid the disintegration 
of the GMS based matrix into smaller fragments to enhance the bioerosion and 
bioabsorption of the GMS based implants. However, in addition to accelerating the 
disintegration of the GMS matrix, the erosion enhancers decreased the release duration of 
cefazolin. Among the investigated erosion enhancers, only the combination of Tween 80 
and PEG 8000 was found to aid the erosion of the matrix with the minimum decrease in 
the release duration as compared to a matrix with no erosion enhancers. Thus, the content 
of Tween 80 and PEG 8000 in the matrix was optimized with respect to the erosion and 
release characteristics. The optimal formulation GMS 34 sustained the release of cefazolin 
for 25 hours and completely disintegrated in 27 hours. 
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1. Introduction 
Prophylactic antibiotics and aseptic techniques have become routine aspects of 
care in most major surgical procedures in order to prevent the economical, physical and 
psychological complications associated with postoperative wound infections (1,2). The 
prophylactic antibiotics are effective in combating the infection when they are administered 
in such a way that provides adequate antibiotic concentrations at the site of the expected 
infection (surgical wound) during and after the surgical procedure. Cephalosporins are the 
antibiotics of choice for the vast majority of surgeries, cefazolin being the dominant choice 
due to its relatively longer half-life (2). 
Antibiotics are usually administered intravenously and this is potentially toxic 
because of the high systemic concentrations. The systemic administration fails to achieve 
effe~tive concentrations at the surgical site when the blood supply is compromised (3). 
The local delivery of antibiotics has been used for the treatment of osteomyelitis, soft 
tissues and wound infections (4,5). Antibiotic loaded polymethylmethacrylate (P:M:MA) 
bone cement was first introduced by Buchholz and Engelbrecht as a prophylactic measure 
in total hip replacement surgeries (6). Barton and Moir reported the advantages of the 
local delivery of antibiotics from P:M:MA implants over the systemic administration of 
antibiotics in the prevention of post-operative wound infections (7). However, since 
P:M:MA is a non-biodegradable material, a surgical procedure is required for its removal 
from the implantation site. The removal of the beads is painful if performed without 
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anesthesia, also, there is a possibility of reinfecting the wound during the bead removal 
operation (5). 
The problems associated with non-biodegradable carriers can be solved by using 
biodegradable materials. The field of synthetic biodegradable polymers (poly a-esters, 
poly-lactic acid, polyanhydrides, poly lactic/glycolic acid (PLGA) , etc.) has been widely 
explored. The synthetic polymers require extensive toxicological and biocompatibility 
studies in order to ascertain their safety for human use. Only few polymers such as PLGA 
are accepted for human use. This is due to the lack of toxicological data about the vast 
majority of synthetic polymers. The compilation of such data requires long time and large 
amounts of money, in order to verify the safety of the new polymers for human use. For 
these reasons, the field of natural biodegradable materials for drug delivery continues to be 
an active area of research despite the advent of synthetic biodegradable polymers. Natural 
materials are attractive primarily because they are products of living organisms and their 
fate in the body is known. In addition to that, they are readily available and relatively 
. . 
InexpensIve. 
Glyceryl monostearate (GMS) is a natural product found in animal fat and 
hydrogenated vegetable oils. Also, GMS is a substrate in the human metabolism and 
biosynthesis of lipids (8). The knowledge about the safe disposition of GMS in human 
body should greatly facilitate the FDA approval of the use of GMS as a biocompatible, 
bioerodible, biodegradable, implantable matrix for the delivery of drugs. 
Being biologically inert, having well defined metabolism pathways in addition to 
being easy to handle, process and formulate into a delivery system promote GMS as a 
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good biodegradable drug delivery carriers candidate. Several methods can be used for the 
preparation of GMS based devices, such as melt-casting, spray congealing, evaporation, 
compression, etc. The different preparation methods vary in their complexity and costs. 
Also, stability of the incorporated drug, drug release kinetics, reproducibility of release 
and bioerosion of the devices are expected to be influenced by the preparation method. In 
case of cefazolin, both its high aqueous solubility (325 mg/mI) and instability create 
challenges in the course of development and preparation of a sustained release matrix to 
deliver cefazolin. Melt-casting has been used by Peri et al (9) for the preparation of 
cefuroxime loaded GMS devices. The introduction of heat during the manufacturing 
process had contributed to the degradation of cefuroxime (9). The melt-casting method 
was also investigated as a preparation method for the cefazolin devices and resulted in the 
degradation of the loaded cefazolin due to the use of heat during the preparation 
procedure. Among the above mentioned preparation methods, only the compression 
method does not involve the exposure of the loaded drug to heat, therefore the 
compression method was selected for evaluation as a preparation method of cefazolin 
loaded GMS devices. 
Cefazolin's instability was expected to complicate the quantification of cefazolin in 
the in vitro release studies, due to the degradation of the released cefazolin in the release 
medium. A suitable in vitro release method that prevents/minimizes the degradation of 
cefazolin after its release was required to be developed. 
The disintegration of the GMS matrix into smaller fragments, increases the surface 
area of GMS that comes in contact with the biological fluids and tissues in the 
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implantation site. The in vivo disintegration of the matrix was expected to accelerate its 
bioerosion and absorption from the implantation site. Therefore, excipients that cause the 
disintegration and enhance the erosion of GMS were investigated. Surfactants increase the 
wettability and the solubility of GMS. in the biological fluids. Also, hydrophilic agents such 
as PEGs can enhance the erosion of the GMS matrix. When the hydrophilic agent is 
released from the matrix, it leaves behind pores and channels rendering the matrix fragile 
and easy to break down, thus aiding in the disintegration of the matrix into smaller 
fragments. In addition to the acceleration of the erosion and disintegration rate of the 
GMS matrix, the erosion enhancers (hydrophilic agents and surfactants) were expected to 
increase the release rate of the loaded drug. An optimization of the content of the erosion 
enhancer(s) in the GMS based matrix was required in order to strike a balance between 
the disintegration and release characteristics which are influenced by the type and content 
of the erosion enhancer in the matrix. 
In order to develop GMS based bioerodible implantable delivery system for the 
local delivery of cefazolin, the above concerns were required to' be addressed. Therefore, 
the specific aims of this study were: 1) to evaluate the compression method as a 
preparation method of the GMS based devices with respect to drug stability and 
reproducibility of release and erosion characteristics, 2) to develop/adopt methods to 
quantitate the amount of cefazolin released from the GMS based devices such as 
spectrophotometry and HPLC assay, 3) to develop/adopt a suitable in vitro release 
method that is simple and minimizes drug degradation after its release from the devices, 
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and 4) to optimize the composition of the GMS based matrix using erosion enhancers with 




Cefazolin sodium USP was obtained from Lyphomed. Glyceryl monostearate 
(GMS) and glyceryl monooleate (GMO) were a gift from Eastman Chemicals. Glyceryl 
monoluarate (GML) was obtained from Laurcidin Inc. PEG 8000 was a free sample from 
Union Carbide. Pluronic Fl27 was obtained from BASF corp. Citric acid and sodium 
EDT A were purchased from Fisher Scientific. HPLC grade acetonitrile, monobasic 
sodium phosphate and dibasic sodium phosphate were purchased from Curtin Matheson 
Scientific Inc. Tween 80 was obtained from leI chemicals. 
2.2 Instruments 
Beckmann ModeillOA pump, Waters Associates Model 710·WISP (auto-
injector), Waters Associates Model 481 LL Spectrophotometer (detector), and Waters 
Associates Microbondapak CI8 column (3.9 mm X 30 cm) were used for the HPLC assay 
of cefazolin. HP diode array spectrophotometer HP 8452 A was used for the UV assay of 
cefazolin. Micro-Mill® grinder (Technilab Instruments, model H37252) was used to mill 
the GMS based mixture. V-mixer (patterson Kelley Company, Twin Shell Dry Blender) 
was used to mix the GMS based powder with cefazolin. Carver Laboratory Press (Fred S. 
Carver Inc., Model C) was used to prepare the devices. Water bath shaker (precision 
Scientific Company) was used to conduct the release studies. U1tramet~ n sonicator 
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(Buehler Ltd.) was used to sonicate the content uniformity samples. Orion Research 
Digital pWmillivoltmeter model 611 was used for pH measurements. 
2.3 Methods 
2.3.1 Cefazolin Assay 
Preparation of Cefazolin Standards - Cefazolin standards (2 - 80 Ilglml) were prepared 
in 0.1 M phosphate buffer (pH 7.4) containing 2 mglml sodium EDTA. An earlier study 
demonstrated the stabilizing effect of EDT A on the degradation of cefazolin in the 
phosphate buffer (10). The presence of sodium EDTA (2 mglml) in the buffer solution 
resulted in a slower degradation of cefazolin as evidenced by the higher concentration of 
the intact cefazolin in the EDT A containing buffer after 75 hours at 370,C (fig. 1). 
Cefazolin HPLC Assay - The HPLC assay was an adaptation of the USP HPLC assay for 
cefazolin (11). Cefazolin was analyzed by reversed phase HPLC using 3.9 mm x 30 cm 
Waters Microbondapak C18 column. The mobile phase was composed of 90% pH 3.6 
phosphate/citrate buffer and 10% acetonitrile. The mobile phase was pumped at a flow 
rate of2.5 mlImin. The cefazolin peak was detected at 273 nm. 
Cefazolin UV Assay - In addition to the HPLC assay, a UV assay was used to quantitate 
cefazolin in the release studies when we had no cefazolin degradation. The absorbance of 
cefazolin was measured at 272 nm using HP diode array spectrophotometer HP 8452 A. 
2.3.2 Preparation ofCefazolin Devices (Matrices) by the Compression Method 
The devices were prepared according to the following steps and procedures: 
1. Mixing of GMS with the Erosion Enhancer(s): 
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GMS and the erosion enhancer(s) were heated to 5°C above the melting point of 
GMS (69°C) in a water bath, while stirring with a glass rod. The molten blend was 
removed from the water bath and allowed to cool to room temperature, while mixing until 
the mol.ten mass solidified. The solidified blend was kept at room temperature for 10 
minutes, then stored in the freezer before any further processing. 
2. Milling of the GMS Based Blend: 
The frozen mass of the GMS based blend was loaded into Micro-Mill® grinder 
along with dry ice. The mass was milled for 30-60 seconds resulting in a very fine powder. 
Dry ice was added to prevent over heating and consequent melting of the milled mass. 
3. Drug Loading by Blending and Verification of Content Uniformity: 
Cefazolin sodium was added to the powdered blend of GMS and the erosion 
enhancer(s) and mixed for 30 minutes in a 50 ml centrifuge tube (Coming®) attached to a 
V-mixer. Three random samples were obtained from the powder after mixing to test for 
content uniformity. Each of the three samples was weighed (20-30 mg) and transferred 
into 100 mI volumetric flasks. Phosphate buffer pH 7.4 (containing 2 mg/ml Na EDTA) 
was added to the volumetric flasks and sonicated for 5 minutes in order to dissolve 
cefazolin sodium. The supernatant was filtered and assayed for cefazolin concentration by 
the UV assay. From the concentration of cefazolin in the filtrate, the actual percentage of 
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cefazolin in each sample was calculated. The results of the three samples were averaged 
and the relative standard deviation (RSD) was determined. Batches with RSD > 10% were 
rejected and the powder was re-mixed and assayed for content uniformity. 
4. Compression of the Blend: 
The cefazolin loaded blend from the previous step was compressed into tablet 
shaped devices, each weighing approximately 200 mg using a Carver Laboratory Press, in 
a die of 9.53 rnm diameter and at a pressure of 1.2 metric ton. The compression at a 
higher pressure caused the material to escape between the punches and the die. 
2.3.3 Release Studies 
The vial method was used to study the release of cefazolin from the GMS based 
devices as shown in figure 2. The GMS based devices were individually placed into 20 ml 
glass vials with 15 mI Phosphate Buffer (0.1 M, pH 7.4) and agitated at 60 oscillations per 
minute in a horizontal water bath shaker at 37°C. The release medium was replaced with 
fresh solution each time a sample was withdrawn. Samples were collected at different time 
intervals, filtered (3 flm membrane), appropriately diluted to fit into the range of the 
calibration curve, then assayed for ~efazolin. In the preliminary evaluation steps, cefazolin 
release form some of the formulations was studied at room temperature. 
2.3.4 Evaluation of Formulations 
Several erosion enhancers were evaluated based on their effect on the erodibility 
and the release duration of the GMS based matrix. Devices were prepared by the 
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compression method. Devices weighed 200 mg and contained 10% w/w cefazolin. The 
different formulations were compared and rated based on the erosion of the device and the 
duration of cefazolin release. 
Evaluation of the Effect of the Erosion Enhancers on the Erosion and Release 
Characteristics: Screening Erosion Enhancers - Several GMS based formulations 
containing hydrophilic agents (pEGs) and/or surfactants as erosion enhancers were 
prepared. The incorporated surfactants were from two categories: a) agents with low HLB 
values which act as wetting agents. The two biocompatible agents used were glyceryl 
monooleate (GMO) and glyceryl monolaurate (GML) and b) agents with high HLB values 
which act as emulsifying and solubilizing agents. The two biocompatible agents used were 
Pluronic F127 (F127) and polyoxyethylene sorbitan monooleate (Tween 80). 
The composition of some of the formulations is listed in table 1. The release studies 
were conducted using the vial release method. The release duration of cefazolin in addition 
to the erosion characteristics of the fonnulations were examined. Pass or Fail judgment 
was established based on the following two criteria: a) The release duration should be at 
least 24 hours at 37°C and b) Complete disintegration of the matrix within 3 .. 5 hours of 
the end of the release period. The formulation should meet both the criteria in order to 
pass. 
Optimization or the Amount of Erosion Enhancers (Tween 80 and PEG 8000) - Two 
factor multilevel factorial design experiments were conducted to optimize the matrix 
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content of erosion enhancers with respect to the release and erosion characteristics; the 
two factors being the content of Tween 80 and PEG 8000 in the GMS based devices. Two 
sets of experiments were conducted with nine different formulations in each set. The 
release studies were conducted in triplicates for each formulation using the vial method at 
37°C. 
In the first set of experiments, the formulation content of Tween 80 and PEG 8000 
varied between 0 - 1 % and 0 - 12.75 %, respectively (table II). In the second set of 
experiments, a narrower range of Tween 80 was used (0 - 0.1 %) and the content of PEG 
8000 ranged between 0 - 11.86 % as listed in table III. 
The amount of cefazolin released was plotted versus the square root of time. The 
cumulative amount of cefazolin released (up to 60% of the drug load) was regressed 
versus the square root of time. The obtained slopes (amount of cefazolin released per 
square root of_time) were used as representatives of "release rates". Release rates, erosion 
characteristics, reproducibility of release and tableting ease were compared in order to find 
the optimal formulation. 
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3. Results and Discussion 
3.1 Cefazolin Assay 
3.1.1 HPLC Assay 
Typical chromatograms of cefazolin standards are shown in figure 3. The HPLC 
assay showed linearity (fig. 4) and reproducibility over the range of 4 - 80 Jlglml. Day to 
day variability was acceptable as determined from the relative standard deviation (RSD = 
2.2%) of the slopes of the calibration curves (77854 ± 1732) (n = 10). 
3.1.2 UV Assay 
The UV assay was linear (fig. 5) and reproducible over the range of 4 - 40 Jlglml. 
The UV assay was reliable and more convenient than the HPLC assay, provided that, there 
was no interference with the drug's spectrum by degradation product(s) and by the matrix 
component. 
When assayed for cefazolin by the HPLC and the UV assays, samples collected 
during the release studies at intervals shorter than 12 - 15 hours had the following 
attributes: 
1. Absence of degradation products' peaks in the HPLC chromatograms (fig. 6). 
2. Absence of shifts in the UV spectrum (the shift in the spectrum could signify the 
presence of degradation products). 
3. Absence of interference with the cefazolin UV spectrum by the matrix components. 
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4. Lack of significant difference between the results of the UV and HPLC assays. 
Figure 7 shows a linear relationship between the detennined cefazolin concentrations by 
the UV and the HPLC assays, with a correlation coefficient of 0.998 and a slope of 0.98 
(r = 0.995). 
The UV assay was equivalent to the HPLC 'assay in the determination of cefazolin 
concentrations in the release medium when no cefazolin degradation was observed. 
Therefore, the UV assay instead of the HPLC assay was used for the determination of 
cefazolin sodium concentration in the release studies' samples. 
3.2 Evaluation of the Compression Method 
The melt-casting and spray congealing methods introduce heat in order to melt the 
GMS (70-75°C), then the drug is suspended in the molten mass. The molten mass is either 
cast into molds and left to congeal (melt-casting), or sprayed to congeal into small spheres 
(spray congealing). The introduction of heat is expected to lead to the degradation of the 
heat susceptible cefazolin. Sedimentation of the dispersed drug might occur during the 
congealing of the molten mass leading to a nonuniform distribution of the drug in the 
devices and consequently resulting in irreproducible release profiles within the same 
batches. 
The compression method avoided the use of heat and hence no drug degradation 
during the preparation of the devices. The release of cefazolin from the compressed 
devices was reproducible due to the good content uniformity within each device and 
among the devices of the same batch (see results offormulation evaluation). 
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The disintegration of the device into small particles facilitates the biodegradation 
and the absorption of the matrix. The melt-casting and the spray congealing methods lead 
to the fusion of the molten material into a continuous solid mass (fig. 8a), and when the 
loaded drug is completely released, it leaves behind a strongly structured skeleton, which 
is difficult to disintegrate and break down into smaller particulates. The above explains the 
observed failure of the melt-cast devices to disintegrate in the release medium in our 
previous investigation, even after the release of all its drug load. In contrast, the devices 
that were .prepared by the compression method and contained erosion enhancers, 
completely disintegrated into a slurry in the release medium within 3 - 5 hours of total 
release of the loaded drug (see results of formulation evaluation), Preparation of the 
devices by the direct compression of fine powdered materials created devices that were 
strongly bound at the surface, while the material inside was not packed (not fused) that 
much due to the presence of intraparticulate air space (Fig. 8b). When the loaded drug 
was released from the device, it left behind a weak skeleton that readily broke down and 
disintegrated with the help erosion enhancers. The disintegration of the devices would 
increase its ability to bioerode and being bioabsorbed when implanted in vivo. 
Along with the faster (easier) disintegration, a compressed matrix is expected to 
exhibit faster release rate of cefazolin than a melt -cast or spray congealed matrix of 
identical composition. This is due to the fact that the loose structure of the compressed 
matrix offers less resistance to the permeation of the release medium into the matrix and 
therefore the release of the loaded drug becomes easier. 
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3.3 Evaluation orthe Release Method (the Vial Method) 
The use of USP dissolution test to evaluate the release of an unstable drug such as 
cefazolin from sustained release delivery system can lead to an erroneous interpretation of 
the release profiles. The released unstable drug remains in the release medium at 37°C for 
the entire duration of the release study and undergoes degradation. The extent of drug 
degradation in the release medium increases as time progresses. In this case, the drug 
concentration in the dissolution medium is simultaneously controlled by its release rate 
from the formulation and the drug degradation rate in the dissolution medium. Therefore, 
a correction for drug degradation in the release medium is required in order to determine 
the actual amount of the released drug. This requires studying the degradation kinetics to 
be able to correct for drug degradation. In addition, an analytical method that is capable of 
separating the degradation products from the intact drug (HPLC assay) is required be 
used. The use of a release method that prevents significant degradation of the drug in the 
release medium will eliminate the above mentioned complications associated with drug 
degradation. 
The prevention of significant cefazolin degradation in the release medium was 
achieved by conducting the release studies in vials (vial method). In vial method used in 
this research, the sampling procedure was conducted by the replacement of the entire 
release medium with a fresh solution at frequent time intervals (fig. 2). This sampling 
procedure eliminated the accumulation of drug in the release medium. The released drug 
was frequently removed from the 37°C medium and assayed before it became subject to 
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significant degradation. As discussed above under the UV assay, the frequent removal of 
the released cefazolin from the 37°C water bath resulted in the prevention of significant 
cefazolin degradation in the release samples (fig. 6). This allowed us to use the rapid and 
convenient UV assay for the determination of cefazolin concentrations in the release 
medium. The vial method was therefore, more appropriate and more convenient than the 
USP dissolution method to study the release of the unstable cefazolin from the GMS 
based devices. 
3.4 Evaluation of Formulations for Erosion and Release Characteristics 
The incorporation of an erosion enhancer into the matrix increased the erosion rate 
and decreased the release duration of the matrix. Thus, our goal was to achieve a balance 
between the duration of drug release and erosion characteristics of the matrix. 
3.4.1 EfTect of the Erosion Enhancers on the Erosion and the Release 
Characteristics 
Table IV summarizes the results of the evaluation of the different formulations. 
From table IV, it can be seen that only formulation GMS 8 passed the two criteria with 
respect to the 24 hour release duration of cefazolin and complete erosion within 3 -5 hours 
of release duration. Most of the formulations were rejected based on their release duration 
being shorter than 24 hours. Only formulations GMS 0 and GMS 8 devices were able to 
sustain the release of cefazolin for at least 24 hours at 37°C (fig. 9). However, formulation 
GMS 0 did not disintegrate at the end of release study. The presence of Tween 80 and 
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PEG 8000 in formulation GMS 8 resulted in a complete disintegration of the matrix at the 
end of the 27 hour. The GMS 8 matrix started to erode and disintegrate around the 16th 
hour of the release study and was completely dispersed in the release medium by 27 hours. 
Therefore, only formulations GMS 8 met both the criteria concerning the duration of 
release (24hours)- and erosion (27 hours) of the matrix. Even though, all the other 
formulations failed to meet our criteria for the release duration ·and erosion, they had very 
little variability in their release profiles. 
A linear relationship was obtained when. the cumulative amount of cefazolin 
released from formulation GMS 8 (up to 60%) was plotted vs. the square root of time 
(fig. 10). The release rate (slope) ofcefazolin from the GMS 8 devices was determined to 
be 20.59 %1hr112 (4.12 mglhrll2). 
3.4.2 Optimization of the Amount of Erosion Enhancers in the Matrix (Tween 80 
and PEG 8000) 
First Set of the Optimization Experiments - In this set of experiments, Tween 80 and 
PEG 8000 ranged between 0 - 1% and 0 - 12.75 %, respectively. All the formulations that 
contained more than 0.122 % Tween 80 released the loaded cefazolin and completely 
disintegrated in less than 20 hours (table V). In contrast, in the absence of Tween 80, the 
devices did not disintegrate completely within 30 hours. The presence of Tween 80 at a 
level as low as 0.122% in the formulation led to a complete disintegration of the matrix 
within 30 hours. Therefore, the second set of experiments was planned using a narrower 
range of Tween 80's content with 0.1% as the upper limit. Increasing PEG 8000's content 
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in the GMS devices was expected to result in faster drug release due to the increase in the 
hydrophilicity of the matrix. However, in the absence of Tween 80, increasing the content 
of PEG 8000 in the matrix, slowed the release rate of cefazolin. This can be explained by 
the fact that PEG 8000 has a lower melting point than GMS, and during the compression 
stage, PEG 8000 melts and later cements the matrix upon the release of the pressure. 
Thus, increasing PEG 8000 content in the matrix, in the absence of Tween 80, slowed the 
release rate of cefazolin. PEGs are generally used as lubricants in tablet manufacturing, 
therefore, increasing the content of PEG 8000 reduced the sticking of the formulation to 
the die and punch. 
Second Set of the Optimization Experiments - Based on the results of the first set, a 
narrower range of Tween 80 was used in this set of experiments. The Tween 80 and PEG 
8000 content ranged between 0 - O. 12% and 0 - 11.86 %, respectively. In the presence of 
PEG 8000, the variation of Tween 80 content in the narrow range of 0 - 0.12 % did not 
have a significant effect on cefazolin release duration, as there was no significant 
difference in the release duration among the nine formulations studied in this set (table 
VI). However, the disintegration of the devices was found to be influenced by the amount 
of Tween 80. The presence of Tween 80 at levels ~ 0.02 % did not help in the 
disintegration of the devices. In contrast, increasing Tween 80 content ~ 0.06 % resulted 
in a complete disintegration of the devices in 27 hours. In the presence of Tween 80, PEG 
8000 content (0 - 11.86 %) did not have a significant effect on cefazolin release duration. 
Increasing PEG 8000 content resulted in a more uniform disintegration of the devices and 
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consequently resulted in a more uniform release profile (no sudden accelerations in release 
rate) for the entire release duration. Also, the increase of PEG 8000 content reduced the 
sticking of the formulation to the die and punches. The formulations were rated according 
to their release rate, disintegration, ease of tableting and uniformity of the release profile. 
Formulation GMS 34 (GMS : Tween 80 : PEG 8000; 89.9 : 0.1: 10) was chosen as the 
optimal formulation because it was among the formulations that were relatively slowest in 
release rate, disintegrated completely in 30 hours, were easiest to tablet and had the most 
uniform release profiles (Fig. 11). 
The release of cefazolin from the GMS based formulations followed the square 
root of time kinetics. Further exploration of the effect of the devices' drug load on the 
release kinetics is necessary for the verification of the mechanism and the mathematical 
model for cefazolin release from the OMS based matrices. 
The maximum release duration of cefazolin, from the erodible GMS based devices 
described above, was 25 hours. However, in a clinical setting, cefazolin is required for a 
duration of 1 to 3 days as a prophylactic measure against post-operative wound infections. 
Therefore, the preparation of GMS based devices that sustain the release of cefazolin for 3 
day period will be investigated. 
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4. Conclusions 
Glyceryl Monostearate (GMS), a biocompatible natural material, was found to be 
suitable for the preparation of a sustained release system. The preparation of the GMS 
based devices by the compression method prevented the degradation of the loaded 
cefazolin during the preparation procedure. The compressed devices were easy to prepare 
and yielded reproducible release profiles. Preparing the matrices by compression facilitated 
their disintegration, however it also increased the release rate of the loaded drug. 
The use of the vial method to evaluate the drug release, was successful in the 
prevention of the accumulation of the drug in the release medium. Thus, significant 
cefazolin degradation in the release medium was avoided. The use of UV assay for the 
determination of cefazolin sodium concentration in the samples obtained from the vial 
method was validated and the results were similar to those obtained by the HPLC assay. 
Therefore, UV assay was selected as the assay of choice for the determination of cefazolin 
concentration in the dissolution samples. The lack of degradation product peak in the 
HPLC chromatographs of the release samples, also proves that cefazolin does not degrade 
significantly inside the devices during the release study, even though the devices were 
studied at 37°C during the release studies. 
The incorporation of surfactants as erosion enhancers helped in increasing the 
disintegration of the devices by dispersing them in the dissolution medium. However, 
most of the investigated surfactants increased the disintegration beyond what was needed, 
resulting in a rapid release of the loaded drug. Only in the case of the combination of 
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Tween 80 and PEG 8000 in formulation GMS 8, the release duration was around 24 
hours and the devices completely disintegrated at the end of the 27 hours. 
Two factor multilevel factorial design was used to optimize the composition of the 
GMS based matrix with respect to their release duration and erosion characteristics. The 
two factors being the content of Tween 80 and PEG 8000. Nine different formulations 
were prepared varying in their content of Tween 80 and PEG 8000. Formulation GMS 34 
was found to be the optimal formulation. This formulation sustained the release of 
cefazolin over a period of 25 hours and completely disintegrated in 27 hours. In addition, 
this formulation was easy to tablet and exhibited uniform and reproducible release profiles. 
It was found that the presence of Tween 80 was essential for the matrix to erode. 
The presence of PEG 8000 improved the uniformity of the disintegration of the devices 
and consequently improved the uniformity of cefazolin release during the release duration. 
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Table I. Composition of some of the formulations prepared to evaluate the erosion 





























* The GMS in the GMS 0 formulation was used as received without milling it. 
GMS: glyceryl mono stearate, GMO: glyceryl monooleate, GML: glyceryl monoluarate, 
PEG 8000 : polyethylene glycol 8000, Tween 80: polyoxyethylene sorbitan monooleate 
and F127: Pluronic" F127. 
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Table II. Composition of the formulations prepared for the first set of optimization 
experiments. The percentages of Tween 80 and PEG 8000 in this set were based on two 
factor multilevel factorial design, in which the limits for Tween 80 and PEG 8000 were 0 -
1 % and 0 - 10 %, respectively. 
Formulation # % PEG 8000 % Tween 80 %GMS 
GMSO a a 100 
GMS20 10 0 90 
GMS21 1 0 99 
GMS22 10 1 89 
GMS23 0 0.5 99.5 
GMS24 12.75 0.5 86.75 
GMS25 5 0 95 
GMS26 5.06 0.122 94.8 
GMS27 5 0.5 94.5 
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Table m. Composition of the formulations prepared for the second set of optimization 
experiments. The percentages of Tween 80 and PEG 8000 in this set were based on two 
factor multilevel factorial design, in which the limits for Tween 80 and PEG 8000 were 
0.02 - 1 % and 1 - 10 %, respectively. 
Formulation # %PEGSOOO % Tween 80 %GMS 
GMS31 1 0.02 98.98 
GMS32 10 0.02 89.98 
GMS33 1 0.1 98.90 
GMS34 10 0.1 89.90 
GMS35 0 0.06 99.94 
GMS36 II.S6 0.06 88.08 
GMS37 5.5 0 94.50 
GMS38 5.5 0.12 94.38 
GMS39 5.5 0.06 94.44 
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Table IV. Summary of the results of the initial screening (evaluation) of the different 
formulations and their release and erosion characteristics. F or a formulation to pass, it 
should sustain the release of cefazolin for at least 24 hours at 37°C and completely 
disintegrate within 3 - 5 hours of the end of the release period. 
Formulation # Duration of release Matrix condition at the PasslFail 
in hours end of the release study 
GMSO 30 physically intact, but soft Fail 
GMS 1* 24 dispersion! slurry Fail 
GMS2* 12 dispersion! slurry Fail 
GMS4 6-9 dispersion! slurry Fail 
GMSS* 12 dispersion! slurry Fail 
GMS6* 12 dispersion! slurry Fail 
GMS7 5-8 dispersion! slurry Fail 
OMS 8 24 dispersion! slurry Pass 
GMS9 6-9 dispersion! slurry Fail 
OMS 10 6-9 dispersion! slurry Fail 
GMS 11 within one hour dispersion! slurry Fail 
OMS 12 - 6-9 dispersion! slurry Fail 
GMS 13 6-9 dispersion! slurry Fail 
The release studies were conducted using the vial method at 37°C or at room temperature. 
* Denotes that the release studies were conducted at room temperature. 
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Table V. The results of the first set of the optimization experiments. The aim of 
experiments was to optimize the content of PEG 8000 and Tween 80 in the GMS based 
devices. Devices were prepared by compression, weighed approximately 200 mg and 
loaded with 10% w/w cefazolin. (See table II for the composition of each formulation) 
Formulation # Release Rate (mglhrll2) Release Duration Time for Complete 
Mean ± SO (n=3) (hour) Disintegration (hour) 
GMSO 2.96 ± 0.17 36 - 40 * 
GMS20 3.22 ± 0.30 37 * 
GMS21 3.47±0.11 37 • 
GMS22 5.41 ± 0.18 12 12 
GMS23 4.49±O.15 16 18 
GMS24 5.09± 0.22 16 18 
GMS25 3.51 ± 0.22 30 * 
GMS26 3.65±0.19 27 30 
GMS27 4.27 ± 0.05 19 19 
• The devices were not completely disintegrated after 30 hours of the start of the release 
study. 
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Table VI. The results of the second set of the optimization experiments. The aim of the 
experiments was to optimize the content of PEG 8000 and Tween 80 in the GMS based 
devices. Devices were prepared by compression, weighed approximately 200 mg and 
loaded with 10% w/w cefazolin. (See table III for the composition of each formulation) 
Formulation # Release Rate (mglhrll2) Release Duration Complete 
Mean ± SD (n=3) (hour) Disintegration (hour) 
GMS31 3.82 ± 0.06 2S * 
GMS32 3.83±0.14 2S * 
GMS33 3.17 ± 0.07 25 27 
GMS34 3.94 ± 0.09 25 27 
GMS3S 3.72 ± 0.09 25 27 
GMS36 4.11 ± 0.17 25 27 
GMS37 3.84 ± 0.06 25 * 
GMS38 4.05 ± 0.07 25 27 
GMS39 3.81 ± 0.05 25 27 
* The devices were not completely disintegrated after 30 hours of the start of the release 
study. 
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Figure 1. Demonstration of EDT A effect on the degradation of cefazolin in phosphate buffer (0.1 M, pH 7.4). The presence of EDT A in 
the buffer solution resulted in a slower degradation of cefazolin. ~ ~ 
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Figure 2. Schematic diagram illustrating the sampling and the release medium replacement 
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Figure 4. Representative HPLC calibration curve of cefazolin. 
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Figure 6. Demonstration of the lack of cefazolin degradation products' peaks in samples withdrawn after intelVals of (a) 3 hours and 
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Figure 7. Correlation between the UV and HPLC determination of cefazolin 
concentrations in the release samples. A linear relationship was obtained with a slope of 
0.98 with a correlation of 0.998 (R2 = 0.995), indicating no significant difference between 
the concentrations determined by the UV and the HPLC assays. 
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Figure 8. Schematic representation of matrices prepared~ (a) by melting techniques (melt-
casting or spray congealing), and (b) by compression method. The melting of the GMS 
leads to the fusion of its particulates into a continuous mass ( a), which is difficult to 
disintegrate and break down into smaller particulates. The direct compression of fine 
powdered materials creates devices that are strongly bound at the surface, while the 
material inside is not packed that much due to the presence of intraparticulate air space 
(b). Therefore, the compressed devices readily break down and disintegrate. 
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Figure 9. Release profiles ofcefazolin from formulations GMS 0 and GMS 8 (n=2). 
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Figure 10. Release profile ofcefazolin from formulation GMS 8. The graph shows that the 
amount of drug released is directly proportional to square root of time. Regression of the 
cumulative amount released versus the square root of time yielded a slope of 20.59 %/hrI12 
(4.12 mg! hrl12). 
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Figure 11. Release profile of cefazolin from the optimal OMS based formulation (OMS 
34). The graph shows that the amount of drug released is directly proportional to square 
root of time. Regression of the cumulative amount released versus the square root of time 
yielded a slope of 19.70 ± 0.43 %/hr1f2 (3.94 ± 0.09 mglhrll2) (n=3). 
CHAPTERID 
GLYCERYL MONOSTEARATE BASED IMPLANTS FOR THE SITE-SPECIFIC 




The goal of this study was to design an implantable delivery system based on GMS 
for the delivery of antibiotics. A rational approach was to study the release of antibiotics 
under conditions that simulate the in vivo implantation conditions to be able to predict the 
release characteristics from the implantable devices when they are actually used in vivo. 
Also, identifying the release mechanism and evaluating the factors that influence the 
release characteristics of drugs from the GMS based matrix was necessary to design 
matrices that can yield a desired release rate or duration. 
Cefazolin devices were implanted into agar gel and their release was monitored 
(gel release method). The implantation into gel simulates the in vivo implantation. There 
was no significant difference between the release profiles, when the release of cefazolin 
was conducted by the gel or the vial methods. Based on the similarity of the release 
profiles by the two methods, it is expected that the release of cefazolin in vivo will not be 
significantly different from that in the vial method. The gel method was cumbersome and 
invasive, therefore the vial release method was used to evaluate the release of cefazolin 
from the GMS based devices. 
The effect of drug load and surface area of the matrix on the release of cefazolin 
were evaluated. The release of cefazolin from the GMS based matrix followed the square 
root of time. Cefazolin release rate was found to be directly proportional to cefazolin load 
and the surface area of matrix, indicating that the release of cefazolin follows the release 
kinetics of a freely soluble drug from an insoluble matrix and hence the release of cefazolin 
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is a diffusion controlled process. The effect of drug load (A) and surface area (SA) on the 
release rate (Q / Ji ) were determined and the release rate of cefazolin was described by 
the following equation: 
Q / Jt = 0.24 A SA 
Based on this equation, we can design a variety of GMS matrices that would result in a 
desired release rate or release duration. 
The effect of loaded drug solubility on the release kinetics were determined by 
comparing the release kinetics of the poorly water soluble ciprofloxacin (0.16 mg/ml) to 
that of the highly water soluble cefazolin (325 mg/ml). The release duration of 
ciprofloxacin (80 hours) was longer than that of cefazolin (25 hours) from identical GMS 
matrices. Due to its poor solubility, the release of ciprofloxacin was a dissolution 
controlled process and hence followed zero order release kinetics. 
The GMS matrix was coated with GMS based mixtures in order to extend the 
release of cefazolin for a three day period. The coating of cefazolin loaded devices delayed 
the release onset of cefazolin. The use of a combination of devices that were coated with 
different coating mixtures was successful in achieving a sequential release that lasted for 
nearly three days. 
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1. Introduction 
Various release methods such as the vial method, the continuous flow method, the 
constant rotation method and the USP dissolution, have been used for the in vitro 
evaluation of drug release from implants (1 - 6). These methods were designed to control 
the influence of variables such as sink condition, temperature, reproducibility of sampling 
and the thickness of the difIUsion layer around the surface of the matrix on the results of 
the release studies. The above listed in vitro release methods involve placing the 
implantable matrix in direct contact with an aqueous solution. However, implants are 
designed to be placed in a surgical wound, where they will be surrounded by tissues and 
intracellular fluids. Under the implantation conditions, the drug difIUses from the implants 
to the surrounding tissues then cleared from there by hemoperfusion. Therefore, to 
simulate the in vivo implantation situation, the implants need to be in contact with release 
media that simulate the tissues (usually subcutaneous tissues) in the wound area. The 
intracellular matrix of the subcutaneous tissues is mainly composed of collagen, 
mycopolysaccharides and water. Protein (collagen) and polysaccharide (agar) gels could 
be used to simulate the subcutaneous tissues due to the close resemblance between the 
gels and the subcutaneous matrix in composition, rheologic behavior and water content. 
Thus, the release from implants implanted in an agar or collagen gels was expected to 
closely simulate the in vivo release of these implants. In our study, the use of agar gel (gel 
release method) was evaluated for studying the release of cefazolin from the GMS based 
matrices. The gel release method was compared to the vial method in order to determine a 
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suitable release method for studying and characterizing the release kinetics of cefazolin 
from the GMS based matrices. 
The GMS based matrices were expected to behave as an insoluble matrix type 
system Drug release from an insoluble matrix is generally achieved by the penetration of 
the release medium into the matrix, the dissolution of the drug, followed by the diffusion 
of the drug solution through the channels and pores of the matrix. Therefore, the 
penetration of the matrix by the release medium, the dissolution and the diffusion of the 
drug in addition to the erosion of the matrix have a significant effect on both the drug 
release duration and kinetics (7). As shown previously (chapter IT), the release of cefazoIin 
from the optimal uncoated GMS based matrix was proportional to the square root of time 
as long as the matrix was intact (maintained a constant surface area) and the total amount 
released was less than 70% of the load. Several equations (8 - 10) have been derived to 
describe the release of water soluble drugs from an insoluble matrix. In these equations, 
the amount of drug release per square root of time (release rate) is be proportional to 
either the drug load or the square root of the drug load depending on the extent of the 
solubility of the drug in the release medium. The solubility of the incorporated drug plays a 
significant role on the release duration and kinetics. The incorporation of an antibiotic with 
a poor solubility such as ciprofloxacin (0.16 mg/ml at pH 7.4, 37°C) was expected to have 
a longer release duration from the GMS based matrices compared to that of an antibiotic 
of a high solubility such as cefazolin (325 mg/ml) (11, 12). Also, the release kinetics and 
the equation that describes the release of ciprofloxacin were expected to be different from 
those of cefazolin from identical GMS based matrix. 
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The high water solubility of cefazolin hindered the prolongation of cefazolin 
beyond 25 hours from the GMS based devices. However, in clinical settings, cefazolin is 
administered parenterally for a duration of 1 to 3 days as a prophylactic measure against 
post operative infections (13). Therefore, a three day release duration of cefazolin was 
desired to satisfy the clinical requirements. There are several approaches (coating, 
encapsulating) that can be used to sustain the release of such a highly soluble drug for a 
longer period. These approaches vary in their cost and feasibility. Dry coating (14) 
represents a simple feasible approach, where the cefazolin loaded cores are coated with a 
layer of GMS based mixture to retard and sustain the release of cefazolin for a longer 
period than achieved by uncoated matrix. 
In order to design a GMS based implantable delivery system, the specific aims of 
this study were: 1) to evaluate the use of the gel release method and compare it to the vial 
method, 2) to characterize the release kinetics of cefazolin from the GMS 34 matrix, 3) to 
determine the effect of drug solubility on the release kinetics and duration from the GMS 




Cefazolin sodium USP was obtained from Lyphomed. Ciprofloxacin was a gift 
from Cipla Pharmaceutical Company. Glyceryl monostearate (GMS) was a gift from 
Eastman Chemicals. PEG 8000 was a gift from Union Carbide. Sodium EDTA was 
purchased from Fisher Scientific. Monobasic sodium phosphate, dib a sic sodium 
phosphate, HPLC grade acetonitrile, phosphoric acid and triethylamine were purchased 
from Curtin Matheson Scientific Inc. Granulated agar was obtained from Becton 
Dickinson. Tween 80 was obtained from ICI chemicals. 
2.2 Instruments 
Beckmann Model lIOA pump, Waters Associates Model 710 WISP (auto-
injector), Waters Associates Model 481 LL Spectrophotometer (UVNis. detector), and 
Waters Associates Microbondapak CI8 column (3.9 mm X 30 cm) were used for the 
HPLC assay of cefazolin and ciprofloxacin. lIP diode array spectrophotometer lIP 8452 A 
was used for the UV assay of cefazolin. Micro-MillCl!> grinder (Technilab Instruments, 
model H37252) was used to mill the GMS based mixture. V-mixer (Patterson Kelley 
Company, Twin Shell Dry Blender) was used to mix the GMS based powders with 
cefazolin or ciprofloxacin. Carver Laboratory Press (Fred S. Carver Inc., Model C) was 
used to prepare the compressed devices. Water bath shaker (Precision Scientific 
Company) was used to conduct the vial release studies. USP dissolution apparatus IT was 
used to conduct the release studies of ciprofloxacin. Ultramet~ IT sonicator (Buehler Ltd.) 
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was used to ensure the solubility of the drugs in the extraction solutions. Orion Research 
Digital pH/millivoltmeter model 611 was used for pH measurements. 
2.3 Methods 
2.3.1 Cefazolin UV and HPLC Assays 
Cefazolin UV assay (as described in chapter IT) was used to quantify cefazolin in 
the release and the content uniformity samples. Cefazolin HPLC assay (see chapter II) was 
used to validate the recovery of cefazolin from the agar gel samples. 
2.3.2 Ciprofloxacin HPLC Assay 
The USP HPLC assay for ciprofloxacin was used to determine ciprofloxacin 
concentrations in the release and the content uniformity samples (15). Ciprofloxacin was 
analyzed by reversed phase HPLC using 3.9 mm x 30 cm Waters Microbondapak CI8 
column. The mobile phase was composed of87% 0.025M phosphoric acid adjusted to pH 
3 by triethylamine and 13% acetonitrile. The mobile phase was pumped at a flow rate of 
1.7 mVmin. The ciprofloxacin peak was detected at 278 nm. 
2.3.3 Preparation of Devices (Matrices) 
Cefazolin and ciprofloxacin devices were prepared by the compression method, as 
described in chapter II. Content uniformity tests were conducted on the powdered mixture 
(cefazolin + GMS based formulation) before the compression step (as in chapter IT). 
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2.3.4 Release Studies 
Gel Method - This in vitro release method was conducted by the implantation of the 
cefazolin devices into agar gel as described below. The agar crystals were dissolved in 
boiling phosphate buffer (PH 7.4) to prepare 1.5 % agar solution. Twenty gram of the hot 
agar solution was poured into a petri dish and left to congeal. A hole, equivalent in size to 
one matrix, was made in the gel at the center of the agar plate. One matrix (GMS 34, 200 
mg, 10 % w/w cefazolin, 9.53 mm) was implanted in the hole. Another 20 gram of the hot 
agar solution was poured on top of the first layer of gel and left to congeal. The plate was 
covered and placed in a 37°C oven. Several agar plates implanted with cefazolin devices 
were prepared at the same time. Samples were collected at 6, 12, 24, 36, 44, 77 and 96 
hours. At each sampling time, one plate was removed from the oven. Using a guide 
template, the plate was divided into four sampling zones (Fig. 1), and three samples 
(approx. 600 mg each) were removed from each zone using a cork borer ( size 4, 8 nun in 
diameter). 
Cefazolin was extracted from the samples and its concentration was determined as 
follows: The samples were accurately weighed and dissolved in 15 grams of boiling buffer. 
The solution was cooled (ice bath) and 5 grams ofNaCl was added to precipitate the agar. 
The resultant suspension was weighed, sonicated then centrifuged to obtain a clear 
supernatant. The supernatant was analyzed by the UV assay to determine the 
concentration of cefazolin. 
The concentration of cefazolin in each agar sample was determined and the total 
amount of cefazolin released into the various zones of each plate was calculated based on 
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the weight of each zone. The total amount of cefazolin released from the implanted matrix 
was also calculated at each time point and the release profile was compared to that 
obtained by the vial method. 
The above described extraction method was validated for both the recovery and 
the stability of cefazolin during the extraction procedure as described below. Three agar 
gels with different known concentrations of cefazolin (0.20 , 1.30 and 2.06 mglg) were 
prepared. Cefazolin was extracted from each agar gel. Cefazolin concentration was 
determined by HPLC assay and the recovery was calculated. The HPLC chromatographs 
were examined for the detection of degradation products' peaks. 
Vial Method - The vial method as described in chapter II, was used to study the effect of 
the devices' surface area and drug load on the release kinetics. It was also used to monitor 
the release of cefazolin from the coated matrices. All the studies were conducted in 
triplicates. 
USP Dissolution Method - The release of ciprofloxacin from GMS 34 formulation was 
studied in a USP dissolution apparatus IT (paddle method) at 37°C in 1 liter O.lM 
phosphate buffer (PH 7.4). Two agitation speeds, 50 rpm and 100 rpm were used to 
conduct the release studies (n=3). 
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2.3.4 Kinetics of Drug Release 
Cefazolin Release Kinetics 
Effect of Cefazolin Load in the Matrix on Release Rate - Matrices, differing only in 
their cefazolin load, were prepared in order to study the effect of cefazolin load in the 
GMS 34 matrix on the release rate of cefazolin. The matrices had identical geometrical 
shape, size, weight (200 mg) and formulation composition (GMS 34). The matrices were 
prepared by the compression method using 9.53 mm die. The four different cefazolin load 
studied were 5.34, 9.99, 15.90 and 21.08 % w/w. The release studies were conducted in 
triplicates by the vial release method. The release profiles were plotted versus the square 
root of time. The release rates were determined by calculating the slopes of the lines, using 
only the data points obtained while the matrices were intact (constant surface area) and 
less than 70 % of the loaded cefazolin was released. The release rates were plotted versus 
the corresponding cefazolin load to determine the relationship between the release rate and 
the drug load. 
Effect of Matrix Surface Area on Release Rate - Matrices, differing only in their 
surface areas, were prepared in order to study the effect of the surface area of the GMS 34 
matrix on the release rate of cefazolin. The matrices had identical geometric shape, 
formulation composition (GMS 34), cefazolin load (10 % w/w) and weight (200 mg). The 
different matrices were prepared by the compression method, using different die sizes (7.0, 
9.53 and 10.0 cm in diameter). This resulted in matrices having the following surface 
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areas: 0.163, 0.185 and 0.200 cm2• The release studies were conducted in triplicates by the 
vial release method. The release profiles were plotted versus the square root of time. The 
release rates were obtained by calculating the slopes of the lines, using only the data points 
obtained while the matrices were intact (constant surface area) and less than 70 % of the 
loaded cefazolin was released. The release rates were plotted versus the corresponding 
surface areas to determine the relationship between the release rate and the surface area of 
the matrix. 
Effect of Drug Solubility on Release Kinetics 
Cefazolin has a high water solubility at pH 7.4 (325 mg/ml). In contrast, 
ciprofloxacin has a poor solubility at the same pH (0.16 mg/ml). To study the effect of the 
solubility of the loaded drug on the release kinetics, ciprofloxacin devices were prepared 
(formulation GMS 34) and their release was compared to that of the identical cefazolin 
matrices (same load, formulation, shape, weight, etc.). The ciprofloxacin and the cefazolin 
devices were prepared by the compression method. The devices had 10 % w/w drug load, 
weighed 200 mg and were prepared by compression at a pressure of 1.2 metric tons in a 
9.53 mm die using a Carver Press. The release behavior of ciprofloxacin from the GMS 34 
matrix was evaluated and compared to that of cefazolin. 
2.3.5 Extending the Release Duration of Cefazolin by Dry Coating 
Core matrices were prepared by direct compression of formulation 34 (optimal 
formulation), containing 20 % w/w cefazolin, using a 7 mm die. The core matrices were 
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coated by GMS based formulations using the dry coating technique. The dry coating 
process was conducted according to the following general procedure: 1/3 of the total 
coating material was placed in a 9.53 mm die over the lower punch and manually 
compressed to level this first layer. The core is placed in the center of the die over the first 
layer. The remaining (2/3) of the coating material was placed on top of the core and 
compressed using CaIVer Press at a pressure of 1 metric ton. Figure 2 illustrates the dry 
coating process. Table I summarizes the composition of the different coated matrices. 
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3. Results 
3.1 The Gel Release Method 
3.1.1 Validation of Cefazolin Extraction from the Agar Gel 
The recovery method used was found to be valid based on the following findings: 
a) the recovery samples showed no evidence of degradation of cefazolin during the 
extraction process, b) all the spiked cefazolin was recovered intact (97 - 106 % recovery), 
and c) the relative standard deviation of all the recovery samples was less than 10%. Table 
IT summarizes the results of the recovery of cefazolin from the agar gel at concentrations 
of 0.20, 1.30 and 2.06 mglg in gel. Since the recovery process did not result in the 
degradation of cefazolin, the UV assay for cefazolin was used to determine the 
concentration of cefazolin in the agar gel samples of the release study. 
3.1.2 Cefazolin Release into the Agar Gel 
Figure 3 shows the spatial release of cefazolin into the agar gel plate at different 
time intervals. Cefazolin was released from the matrix into the surrounding gel and as time 
progressed, the total amount of cefazolin released from the matrix increased leading to the 
increase of cefazolin concentration in the various zones. Initially, the concentration of 
cefazolin in zone 1 was the highest and cefazolin concentration in the gel decreased as the 
distance from the implant increased. After 24 hours, the concentration of cefazolin in the 
first zone started to decrease, leading to an increase in cefazolin concentrations in the 
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outer zones (zones 2, 3 and 4). Eventually the concentration of cefazolin in the entire plate 
will reach a constant value. Almost 100% of the loaded cefazolin was released within 24 
hours. The implants turned into a pasty mass 24 hour after implantation. 
3.1.3 Comparison of Cefazolin Release from GMS 34 Matrix by the Vial and the 
Gel Release Methods 
The GMS matrix released 98 % of its cefazolin load within 24 hours in the gel 
method. This is comparable to the release by the vial method (fig. 4). The total amount of 
cefazolin released in the agar gel was calculated by cumulating the amounts found in the 
four zones and the amount of cefazolin in the gel portion (approx. 300 mg) that 
immediately surrounded the implanted device. The gel portion that immediately 
surrounded the implanted device was not assayed for its content of cefazolin due to the 
difficulty in separating this gel portion intact from the implanted device. Cefazolin 
concentration in this gel portion was assumed to be equal to that in the first zone. 
Almost 100 % of cefazolin was released by 24 hours and since no cefazolin 
degradation was detected in the first 24 hours, therefore it can be assumed that, there was 
no interference by the degradation products with the UV assay of cefazolin released from 
the matrix. Degradation products were detected only after 36 hours of the beginning of 
the release study. The degradation of cefazolin was a result of the extended exposure of 
the released cefazolin to 37°C. Unlike in the vial method, in the gel method the released 
cefazolin remained in the release medium (gel) for the entire duration of the release study. 
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3.2 Cefazolin Release Kinetics from the Optimal GMS Based Formulation (GMS 
34) 
3.2.1 Effect of Cefazolin Load on the Release Rate 
As seen in figure 5, cefazolin release from the matrices with the different cefazolin 
loads (5.34, 9.99, 15.90 and 21.08 % w/w) was proportional to the square root of time. 
Table ill lists the release rates of these different matrices. The release rate of cefazolin 
was found to be directly proportional to the drug load of the matrix (fig. 6). The 
relationship between the release rate (QI Ji) and cefazolin load (A) can be described by 
the following equation (r2= 0.98): 
QlJi=0.44A (Eq. 1) 
where (Q I Ji) is the release rate in mg/hr1l2 and (A) is the load in % w/w. Equation 1 is 
written as follows when the load (A) is described in mg/cm3: 
QI Ji= 0.038 A (Eq.2) 
Equation 1 or 2 can be used to predict the release rate of cefazolin based on the cefazolin 
load in the GMS 34 matrix, when the surface area of matrix is kept at 1.85 cm2• 
3.2.2 Effect of Surface Area of the Matrix on Cefazolin Release Rate 
As seen from figure 7, cefazolin release from the matrices with the different 
surface areas (1.63, 1.85 and 2.00 cm2) was proportional to the square root of time. Table 
IV lists the release rates of these different matrices. The release rate of cefazolin was 
found to be directly proportional to the surface area of the matrix. The relationship 
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between the release rate (QI..Ji) and the surface area of the matrix (SA) can be 
described by the following equation (r2 = 0.91): 
QI..Ji= 2.4 SA (Eq.3) 
Equation 3 can be used to predict the release rate of cefazolin based on the surface area of 
the matrix GMS 34, when the cefazolin load is 10 % w/w (116.3 mglcm3). 
3.3 Effect of Drug Solubility on Release Kinetics 
3.3.1 Comparison of the Release Kinetics of Cefazolin and Ciprofloxacin 
The release duration of ciprofloxacin was found to be longer than that of cefazolin 
from identical matrix formulation (GMS 34, 10 % w/w) (fig. 9). Cefazolin release duration 
was 25 hours and the release followed square root of time kinetics. In contrast, 
ciprofloxacin release duration was 80 hours (USP Dissolution Apparatus, 50 tpm) and the 
release followed zero order release kinetics for the first 28 hours. After 32 hours, an 
increase of the release rate was noticed, due to the increase in the surface area of the 
matrix after its disintegration into smaller matrices. 
3.3.2 Effect of Agitation on Ciproftoxacin Release Kinetics 
During the first 16 hours, the ciprofloxacin matrices were intact under the two 
agitation rates and the amount of ciprofloxacin released at 50 tpm was identical to that at 
100 tpm (fig. 10). The onset of the disintegration of the ciprofloxacin devices was affected 
by the agitation rate. The disintegration started after 18 and 28 hours at 100 and 50 rpm, 
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respectively. Under the two agitation rates, the disintegration of the devices led to an 
increase in the release rate of ciprotloxacin due to the increase in the surface area of the 
devices. The disintegration of the matrices and the increase of the surface area was faster 
at 100 than at 50 rpm and consequently the release of ciprotloxacin was faster at 100 rpm 
3.4 Extending the Release Duration of Cefazolin by Dry Coating 
The combination of 4 devices; one uncoated and three coated, provided a release 
duration of 2.5 days in vitro (Fig. 11). Each of the devices had a different release onset 
based on the composition of the coating material. Table V summarizes the in vitro 
cefazolin release onset and duration from the different coated and uncoated devices. The 
release of cefazolin from this combination of devices was sequential. The sequential 
release was achieved by a combination of devices, in which one device released for a 
period of time and another device started to release when the release was nearly 
terminated from that previous device and so on. The total in vitro release duration from all 
the devices was 60 hours. All the matrices completely disintegrated and turned into a 




4.1 Comparison of Release by the Vial and the Gel Methods 
Previously, agar gel plates seeded with microorganisms were used to study the 
efficacy and the release of antibiotics from implantable devices in order to mimic the in 
vivo implantation situation (16). Simi1arly, in this study, the release of cefazolin from the 
GMS matrices in the gel method was conducted in order to simulate the in vivo 
implantation conditions, under which the implanted matrices are surrounded by tissues 
rather than buffer solutions. The gel in this case represented the tissues at the implantation 
site with respect to viscosity and water content. The release characteristics of cefazolin 
from the matrices implanted in the gel were expected to be closer to the in vivo release 
than in the vial method. The gel method was intended to be an intermediate step between 
the in vitro (vial method) and the in vivo evaluation of the cefazolin release from the GMS 
matrices. 
By comparing the release profile obtained by the gel and the vial methods, it was 
found that there was no significant difference between the release by the two methods. 
This similarity in the release profiles is due to the high aqueous solubility of cefazolin and 
the fact that 98.5% of the gel is water. The release medium (buffer) in the vial method was 
kept under agitation, which led to a homogenous cefazolin concentration in the entire 
release medium. In contrast, the release medium in the gel method (agar gel) was not 
agitated and the released cefazolin had to diffuse through the gel, driven only by its 
concentration gradient in the agar gel plate. In the case of the vial method, a sample of the 
78 
release medium (buffer) was adequate to describe the entire release medium for the 
determination of the total amount of drug release. However, in the case of the gel method, 
multiple samples to represent the entire area of the gel were required since cefazolin 
concentration was not homogeneous through out the entire gel medium Therefore, 
samples were withdrawn from various zones of the agar plate, where each sample covered 
the entire width of the corresponding zone. The diffusion of the released cefazolin from 
the matrix immediate surrounding gel into the rest of the gel was slower than in the case of 
a buffer solution that was kept under agitation (vial method). The gel portion (approx. 300 
mg) that immediately surrounded the implanted device was not assayed for its content of 
cefazolin due to the difficulty in separating this gel portion intact from the implanted 
device. For the calculation of the total amount of cefazolin released, cefazolin 
concentration in that gel portion was assumed to be equal to that in the first zone, even 
though it should have been much higher at the earlier stages of the release study. Based on 
this fact, it is expected that the release by the gel method is closer to the release by the vial 
method than seen in figure 4. Sampling in the gel method was an invasive process and 
cefazolin extraction from the gel samples was a tedious process. The released cefazolin 
accumulated in the gel and therefore it was liable to degradation as seen in samples 
collected after 36 hours. Based on the similarity of the release profiles between the two 
release methods, it is expected that the in vivo release of cefazolin will not be much 
different from the release in the vial method. All of the above led us to the use of the vial 
method to study the release of cefazolin from the GMS based matrices as the vial method 
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showed comparable results to those obtained by the gel method without the disadvantages 
that are associated with the gel method. 
4.2 Kinetics of Drug Release 
Drug release from an insoluble matrix is generally achieved by the penetration of 
the release medium into the matrix, the dissolution of the drug followed by the diffusion of 
the drug solution through the channels and pores of the matrix. Both the drug dissolution 
rate and the drug solution diffusion play a significant role on the release kinetics and the 
release duration of the drug from the matrix. 
In the case of a highly soluble drug with a rapid dissolution rate and its solubility 
in the release medium (Cs) is much greater than the drug load (concentration) in the matrix 
(A), ie. Cs » A, the release medium penetrates the matrix and instantaneously dissolves 
all the drug in the part of matrix that is penetrated. The incorporated solid drug turns in to 
a solution and its release from the matrix follows the release of a solution entrapped in an 
insoluble matrix (Fick's law, diffusional release) (7, 8, 10). The release of such a drug 
from an insoluble matrix can be described rather well up to 60 % of the loaded drug by the 
following equation: 
Q = 2 A SA -J Dt / Jrr (Eq.4) 
Where Q is the amount of drug released after time t, SA is surface area of the 
matrix, A is the initial concentration of the drug in the matrix (drug load), D is the 
diffusion coefficient of the drug in the release medium and ~ is the tortuosity of the matrix. 
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Another situation arises when the drug solubility in the release medium is less than 
two times the drug load in the matrix, i.e. 2A> Cs• In this case, the release is controlled by 
both the dissolution rate of the drug and the diffusion rate of the drug solution out of the 
matrix and the release of the drug is characterized as diffusion from a moving dissolution 
front. As time progresses, the depletion zone grows and the dissolution front recedes from 
the part of the matrix, in which the drug has been depleted from The release of such a 
drug is described by the Higuchi's equation (diffusional release with a moving dissolution 
front) as shown below (9): 
Q = SA.J(DCs/ 't)(2A - ECs)t (Eq. 5) 
Where Q, SA, D, A, t and t are as defined above, E is the porosity of the matrix 
and Cs is the solubility of the drug in the release medium 
A third case is of a poorly soluble drug with a rather slow dissolution rate. In this 
case the release medium penetrates the matrix, however, the dissolution of the drug is very 
slow and only the dissolved drug diffuses out of the matrix through the pores and 
channels. The rate limiting step in this case is the dissolution of drug in the release 
medium. Therefore, the release rate of such a drug is nearly zero order (8). 
4.2.1 Cefazolin Release Kinetics 
Cefazolin has a vel)' high aqueous solubility (350 mg/ml) with a rapid dissolution 
rate (15 mglcm2.min) (12). Cefazolin's solubility (Cs) exceeds its load (A) in the GMS 
matrix. Therefore, it was expected that its release from the GMS based matrix would 
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follow equation 3 rather than equation 4. Equation 3 implies that the release rate (Q / Ji ) 
is directly proportional to the load (A) and equation 4 suggests that the release rate 
(QI Ji) is proportional to the square root of the drug load (A). Therefore, in order to 
verify which equation does the release of cefazolin from the GMS 34 matrix follows, the 
effect of the drug load (A) on the release rate was examined. 
Experimentally, the release rate (Q / Ji ) was found to be directly proportional to 
cefazolin load (Eq. 1 and 2), proving that the release of cefazolin from the GMS based 
matrix follows equation 4 for the release of highly water soluble drug from an insoluble 
matrix. The release rate was also found to be proportional to the surface area of the matrix: 
(Eq. 3). 
Based on equations 2 and 3, the value of ~ D / 1fT in equation 4 was calculated to 
be 1.7 x 10.4 cmlsec1l2, therefore equation 4 for the release of cefazolin from the GMS 
based matrix can be written as follows: 
Q = 3.4 X 1 0- 4 A SA.Jt (Eq.6) 
Where Q is the amount of cefazolin released (mg) at time t (sec), A is the drug 
load (mg/cm3) and SA is the surface area (cm2) of the matrix. Equation 6 can be written 
as: 
Q = 0.24 A SA.Jt (Eq. 7) 
When time is in hours and the drug load is in % w/w. For the calculation of the release 
rate, equation 7 can be rearranged as follows: 
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Q 1.Jt = 0.24 A SA (Eq.8) 
From equation 8, desired release rate of cefazolin can be obtained based on the load and 
surface area of the GMS 34 matrix. Using equation 8, surface response and contour plots 
were generated (fig. 12a and 12b). From equation 8 and/or plots, the desired release rate 
could be obtained by using different combinations of surface area and load values. 
Equations 6, 7 and 8 can be also used to predict the release of drugs with comparable 
diffusion coefficients and solubility to that of cefazolin' s. 
4.2.2 Effect of Drug Solubility on its Release Kinetics 
As discussed above, the solubility and the dissolution rate of the drug play a 
significant role in the drug release kinetics. The solubility of cefazolin sodium and 
ciprofloxacin Hel at pH 7.4 are 325 and 0.16 mglml, respectively. Due to its high 
solubility, cefazolin release follow square root of time kinetics (diffusional release), 
obeying equation 3 for a highly soluble drug with a fast dissolution rate. In the case of 
ciprofloxacin, the release was found to follow zero order kinetics for the first 28 hours (50 
rpm), signifying that the release of ciprofloxacin is a dissolution controlled process, where 
the rate limiting step is the slow dissolution of ciprofloxacin in the penetrating release 
medium. The release duration of ciprofloxacin (80 hours at 50rpm) was three times longer 
than the release duration of cefazolin (25 hours), indicating the effect of drug solubility on 
the release kinetics form the GMS based matrix. 
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4.2.3 Effect of Agitation on Ciprotloxacin Release kinetics 
If the dissolution of a drug controls the rate of its release from the matrix as in the 
case of a poorly water soluble drug such as ciprofioxacin, the release rate will be 
influenced by the factors that influence dissolution such as the thickness of the diffusion 
boundary layer. The aqueous di:flUsion boundary layer around the matrix offers significant 
resistance to the dissolution of the poorly soluble drug. The agitation rate of the 
dissolution medium affects the thickness of the aqueous di:flUsion boundary layer, the 
higher the agitation rate the thinner is the aqueous di:flUsion boundary layer. If the release 
of ciprofloxacin is solely controlled by its dissolution in the release mediutn, then the faster 
the agitation rate, the faster the release of ciprofloxacin will be. In other words, if the 
prolonged release of ciprofloxacin is only a result of its slow dissolution, the release will 
be faster at a higher agitation rate. Thus, the release studies of ciprofloxacin loaded 
matrices were-conducted at two agitation speeds, 50 and 100 rp~ in order to establish 
whether the release of ciprofloxacin is prolonged (extended) by the matrix (matrix 
controlled release), or the release is simply prolonged because of the slow dissolution of 
ciprofloxacin. If the matrix is truly controlling the release, there should not be any effect of 
agitation on the release kinetics of ciprotloxacin. 
It was found that, there was no significant difference between the release of 
ciprofloxacin under the two agitation rates (50 and 100 rpm) for the first 16 hours during 
which the matrices were intact. Increasing the agitation rate accelerated the onset of the 
matrices' disintegration into smaller fragments (smaller matrices). The matrices started to 
disintegrate around 18 and 28 hours at 100 and 50 rpm, respectively .. The disintegration of 
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the matrix led to an increase in its surface area. This increase in the surface area resulted in 
an increase in the release rate of ciprofolxacin (fig. 10). The release of ciprofloxacin was 
different only after the disintegration of the matrix. The above observation indicated that, 
the increase in the agitation rate led to an acceleration of the matrix disintegration rather 
than directly increasing the release rate of ciprofloxacin from the GMS matrix. Therefore, 
the release of ciprofloxacin was independent of the agitation rate as long as the surface 
area of the matrix was kept constant. The agitation rate was indirectly increasing the 
release rate by accelerating the disintegration of the matrix resulting in an increase of the 
surface area. Thus, the matrix is truly controlling the release rate of ciprofloxacin rather 
than the poor solubility of ciprofloxacin. 
The GMS matrix used for ciprofloxacin delivery was designed for the delivery of 
cefazolin (GMS 34). This matrix was designed to erode 15 -18 hours after complete 
release. Therefore, a more suitable formulation needs to be designed and optimized for the 
delivery of ciprofloxacin. 
4.3 Extending the Release of Cefazolin 
The relatively short release period (25 hours) of cefazolin from the simple 
uncoated GMS matrix is a result of the high aqueous solubility of cefazolin. Dry coating 
approach was employed in order to extend the release duration of cefazolin. In this 
process, cefazolin loaded GMS matrices were coated with different OMS based mixtures. 
The coating layer shielded the cefazolin loaded core from the release medium and delayed 
the onset of cefazolin release from the core matrix. This shielding effect continued as long 
85 
as the coating layer was intact. However, as time progressed the coating layer started to 
swell and break away from the matrix. The swelling of the coating layer created pores and 
channels through which cefazolin was released slowly at the beginnjng into the release 
medium The release became faster as the coating layer became more swollen and started 
to erode- away from the core matrix, eventually exposing the core to the release medium. 
The onset of the swelling and the uncovering of the cores and consequently the onset of 
cefazolin release depend on the composition of the coating layer. 
The combination of several devices that have different drug release onsets is one of 
the approaches used by the pharmaceutical industry in order to provide a continuous 
release of drugs for an extended period of time (17). An example of this approach is the 
Spansule® dosage form designed by Smith Kline & French Laboratories (currently Smith 
Kline & Beecham) (18). Spansule® is a capsule filled with a combination of pellets with 
different drug release onsets. The combination of pellets is designed in such a way that 
produces a continuous release for an extended period of time. Applying the same concept, 
three different coating mixtures were designed to delay the onset of cefazolin release for 
different time periods. The combination of these three coated devices (different coating 
materials) along with an uncoated device resulted in a continuous release of cefazolin for 
2.5 days in vitro. The release of cefazolin from the devices was programmed to be 
sequential, i. e. the release from a device would only start at the time when the release from 
the previous device had been nearly terminated. The release profile of cefazolin from the 




Cefazolin release rate was found to be directly proportional to the drug load and 
the surface area of the matrix, implying that cefazolin release from the optimal GMS 
matrix (GMS 34) follows the release kinetics for a freely water soluble drug from an 
insoluble matrix. The following equation applies for cefazolin release from the optimal 
GMSmatrix: 
Q = 2 A SA.J Dt / 1(, (Eq.4) 
By substituting for .J D / 1fT and rearranging the equation, the release rate of 
cefazolin from the GMS 34 matrix can be described as follows: 
Q 1.Jt = 0.24 A SA (Eq.8) 
Therefore, desired release rate of cefazolin from GMS 34 matrix can be obtained based on 
the drug load and the surface area of the matrix using equation 8. Equation 8 can be also 
utilized to calculate the release rate of other drugs with comparable diffusion coefficient 
and solubility to that of cefazolin' s. 
The maximum release duration from the simple uncoated GMS matrix was about 
25 hours. In order to extend the release of cefazolin for a longer period, cefazolin matrices 
were coated with different coating materials based on GMS, in order to delay the onset of 
cefazolin release. The delay in the release onset depended on the composition of the 
coating material. The combination of four matrices (three coated and one uncoated) 
successfully sustained the in vitro release of cefazolin for 2.5 days. The release profile of 
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cefazolin from this combination was quasi-linear, which is preferred for drug delivery. The 
matrices disintegrated completely and turned into a slurry in the release medium. The in 
vitro disintegration of the matrices is a good indicator of the ability of the matrices to 
erode in vivo, thus facilitating the bioabsorption of the implants from the implantation site. 
The release duration of ciprofloxacin was significantly longer than that of cefazolin 
(25 vs. 80 hours), due to the much lower solubility of ciprofloxacin in the release medium 
(0.088 mglml) compare~, to cefazolin (325 mglml). The agitation rate of the release 
medium did not affect the release rate of ciprofloxacin in the first 16 hours, during which 
the matrices were intact. Thus, the release of ciprofloxacin was controlled (extended) by 
the matrix rather than being solely controlled by the slow dissolution rate and the poor 
solubility of ciprofloxacin. However, increasing the agitation rate increased the 
disintegration rate of the matrix and consequently increased the release rate of 
ciprofloxacin by increasing the matrix surface area. 
Formulation GMS 34 was optimized for the release of cefazolin (25 hour 
duration) and was not suitable for controlling the release of ciprofloxacin (longer than 25 
hours). Thus, a different GMS based formulation could be optimized to control the 
delivery of ciprofloxacin, where the optimal matrix would not disintegrate until most of 
the loaded ciprofioxacin had been released. 
It was found that the cefazolin release into the agar gel was not significantly 
different from its release in the vial method. The similarity between the release profiles of 
cefazolin in the gel and in the vial methods, in addition to the advantages of the vial 
method, confirm the suitability of the vial method for studying the release of cefazolin 
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from the GMS matrices. The in vivo release of cefazolin is not expected to be much 
different than that in vitro. The GMS based matrix turned into a pasty mass 24 hour after 
the implantation into the gel 
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Table I. Composition and weight of the coating materials used to prepare the different 
coated devices, in order to extend the release duration of cefazolin. 
Device # Core Weight (mg) Coating Material 
1 60 GMS 17 
2 60 GMS 1 
3 60 GMS 19 











Mean + SD (n=3) 
96.93+3.14 
97.40 + 2.16 
105.63 + 10.31 
94 
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Table ill. Cefazolin load (A) of the GMS 34 matrices and the corresponding release rates 
( QI Ji). 
Cefazolin Load Cefazolin Load Release Rate (mg/hr112) 
(w/w%) (mg/cm3) Mean ± SD (n=3) 
5.34 62.10 1.98 ± 0.12 
9.99 116.18 4.26 ± 0.09 
15.90 184.92 6.58 ± 0.13 
21.08 245.16 9.57 ± 0.39 
Table IV. Surface areas (SA) of the GMS 34 matrices and the corresponding release rates 
( QI..fi). 





Release Rate (mg/hrIf2) 
Mean ± SD (n=3) 
3.89 ± 0.12 
4.26 ± 0.09 
4.82 ± 0.06 
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Table V. Summary of the in vitro cefazolin release onset and duration from the different 
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Device Zone 
Figure 1. Schematic diagram of the guide template used to divide the agar plate into four 
sampling zones. The width of each zone is 9 mm, the device's zone is 11 mm. 
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1 2 3 4 
Figure 2. Schematic illustration of the dry coating process. 1) Fill 1/3 of the total coating 
material to form the first layer, 2) place the core matrix in the center, 3) fill the remaining 
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Figure 3. Spatial release of cefazolin from the GMS based matrix into the various zones of 
the agar gel plate after the implantation of cefazolin loaded matrix (formulation 34) in the 
center of the agar plate. Cefazolin concentration in zone 1 increased up to 24 hours, 
afterwards the concentration decreased giving rise to the concentrations in the outer 
zones. The termination of the concentration increase (around 24 hours) in zone 1 indicates 
that the release of cefazolin from the matrix was complete (100 % release). This was 
confirmed by the mass balance. 
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Figure 4. Release of cefazolin from the GMS 34 monitored by the vial and the gel 
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Figure 5. Effect of cefazolin load on release rate. The graph shows the release profiles of 
the matrices with cefazolin loads of 5.34 % (.), 9.99 % (_), 15.90 % (.) and 21.08 % 
(.) (n=3). The solid lines are the regression lines, used for the calculation of the release 
rates. 
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Figure 6. Correlation between cefazolin load (A) and release rate ( QI Ji) offormulation 
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Figure 7. Effect of matrix surface area on release rate. The graph shows the release 
profiles of the matrices with surface areas of 1.63 cm2 (+), 1.85 cm2 (_) and 2.00 cm2 (~) 
(n=3). The solid lines are the regression lines, used for the calculation of the release rates. 
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Figure 8. Correlation between matrix surface area (SA) and cefazolin release rate 
(QI Ji) offormulation GMS 34 (n=3). QI Ji = 2.4 SA (r2 ="0.91). 
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Figure 9. Effect of the aqueous solubility of the antibiotic on the release kinetics of 
formulation GMS 34 devices. The graph compares the release profiles and duration of 
cefazolin and ciprofloxacin from identical GMS matrices (n=3). 
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Figure 10. Effect of agitation rate on the release of ciprofloxacin. The increase in the 
agitation rate indirectly increased the release rate via the acceleration of the disintegration 
of matrix into smaller fragments (increased surface area). The graph shows no significant 
difference in the release profile in the first 16 hours, while the matrices were intact under 
the two conditions. The difference started to appear after the disintegration of the 
matrices, which was faster at 100 rpm Thus, the release of ciprofloxacin is controlled 
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Figure 11. Release of cefazolin from a combination of four devices, in addition to the 
individual release profiles (one uncoated and three coated matrices). The release profile 
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Figure 12a. surface response plot of cefazOlin release rate versus cefazo
lin 
drug load and 
the surface area of the GMS matriX. Based on the plot, one can design a matriX with a 
desired release rate by selecting appropriate cefazO
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Figure 12b. Contour plot of cefazolin release rate versus cefazolin drug load and the 
surface area of the GMS matrix. Based on the plot, one can design a matrix with a desired 
release rate by selecting appropriate cefazolin load and matrix surface area. 
CHAPTER IV 
EFFICACY AND PHARMACOKINETICS OF SITE-SPECIFIC (LOCAL) 




Systemic administration of antibiotics has been shown to significantly decrease, but 
not eliminate post-operative wound infections mainly due to the failure in achieving 
adequate levels of antibiotics at the surgical wound. The use of local administration of 
antibiotics is therefore advantageous as a prophylactic measure. Glyceryl monostearate 
(GMS) based biocompatible, bioerodible implants were developed for short term (1-3 
days) delivery of antibiotics. Cefazolin loaded implants were prepared and the efficacy and 
pharmacokinetics of cefazolin delivered locally by these implants were evaluated in 
Sprague-Dawley rats subcutaneously inoculated with staphylococcus aureus, simulating a 
post-operative wound infection. For the efficacy and pharmacokinetic studies, eighteen 
rats were subcutaneously inoculated with 4.5 X 107 CFU of Staphylococcus aureus on the 
dorsum (6 inoculations per rat), and randomly assign into three group of six rats each: (1) 
the control group, in which rats did not receive antibiotics, (2) the intermittent . 1M 
treatment group, in which rats received intermittent 1M injections of 10 mg/kg cefazolin 
every 4 hours (total of 180 mg/kg in three days), and (3) the implant treatment group, in 
which rats were implanted subcutaneously with four Cefazolin-GMS implants in the 
vicinity of the inoculations. The implants were designed to deliver 180 mg/kg cefazolin 
over three day period. For efficacy evaluation, the rats were euthanized after one week 
post-inoculation and abscess count, weight and size were determined in each rat. The rats 
in the control group had developed 21 abscesses out of the 36 inoculations, indicating the 
validity of our infection model. The local delivery of cefazolin resulted in the complete 
eradication of the infection, as there were no abscesses formed in the rats in the implant 
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treatment group. In the intermittent 1M treatment group, only one abscess was formed. 
There was no significant difference in efficacy between the two treatment groups. For the 
evaluation of pharmacokinetics, plasma profiles of cefazolin in the two treatment groups 
were compared. The GMS implants sustained the release of cefazolin for a period of three 
days with very low fluctuation (3-fold), and ranged between 5.5 - 17.5 JIg/mI. However, 
plasma concentrations after the intermittent 1M administration of cefazolin fluctuated 
between 44 - 0.40 Jlg/ml (I IO-fold) every 4 hours. The release rate ofcefazolin from the 
implants was nearly zero order for the entire duration. The bioerosion of the implants was 
determined in an additional group of three rats. These rats were euthanized six weeks post 
implantation and the condition of the implants was examined. Upon opening the 
implantation site, six weeks post-implantation, two out of the 12 implants had completely 
disappeared. The remaining implants were in a pasty form and had lost 20 - 80 % of their 
weight. There was no evidence of irritation or inflammation around the implants indicating 
the biocompatibility of the GMS implants. Overall, the research was successful in 
designing a delivery system that provided a prolonged delivery of cefazotin for three days 
with a near zero order release rate. The system was effective against staphylococcus 




Most of the 23 million patients who undergo surgery annually in the United States 
receive perioperative antimicrobial prophylaxis (1). Despite this practice 500,000 -
920,000 surgical wound infections occur annually, accounting for 24% of all nosocomial 
infections. Such infections contribute substantially to the· morbidity and costs associated 
with surgery. The economical, physical and psychological impact of postoperative wound 
sepsis mandates the use ofproper preventive measures to minimize infections (2). 
State of the art aseptic techniques dramatically reduced, but did not eliminate 
surgical wound infections. Even under laminar flow operating room environments, 
bacteria, can be predictably isolated from the wound surfaces at the close of the surgical 
procedure. Burke et a1. (3) demonstrated that, despite the use of standard aseptic 
techniques staphylococcus aureus was regularly isolated from the operative field. It 
became apparent that aseptic techniques could decrease but not eliminate bacterial 
contamination of the surgical field. Therefore, the possibility should be considered that 
perioperative antibiotics could supplement aseptic techniques in containing the inevitable 
contamination of the operative wound. 
The efficacy of a wide variety of prophylactic antibiotics has been verified for 
hundreds of surgical procedures, when care has been given to provide adequate serum and 
tissue levels of antibiotics during the surgical procedure. Perioperative antibiotics and 
aseptic techniques have become routine aspects of care in most major surgical procedures. 
High -systemic doses of antibiotics are administered perioperatively in order to achieve an 
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effective concentration of antibiotics at the site of the surgery. The antibiotic 
administration has been justified to be continued postoperatively for 2 to 3 days in patients 
who have undergone major surgical procedures (4). 
The antibiotic of choice should have a wide spectrum of action to cover gram-
positive and gram-negative pathogens. Clindamycin, penicillins such as ampicillin and 
aminoglycosides such as gentamicin are frequently used as prophylactic antibiotics. 
Cephalosporins, however, are the drugs of choice for the vast majority of operative 
procedures (4). With a relatively longer half-life (1.8 hours), cefazolin has been the 
dominant choice in most surgical procedures that require prophylaxis (4, 5). 
The recommended dosing of cefazolin as a perioperative prophylactic antibiotic is 
1 g administered IV or 1M one-half to one hour prior to the start of surgery in order to 
achieve adequate antibiotic levels in the serum and the tissues at the beginning of surgery, 
followed by 0.5 to 1 g IV or 1M every 6 to 8 hours for 24 hours postoperatively. In 
surgeries in which the occurrence of infections may be particularly devastating (prosthetic 
arthroplasty), the prophylactic administration of cefazolin may be continued for 3 to 5 
days following the surgery (6). 
The systemic administration of prophylactic antibiotics is potentially toxic because 
of the required large systemic doses in order to provide adequate levels at the surgical site. 
Furthermore, the systemic administration could be ineffective in certain cases in which 
blood supply to the surgical site is compromised due to the poor vascularity and/or the 
necrosis of the surgical site. 
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Systemic continuous infusion of antibiotics such as cefazolin, ceftazidime and 
penicillin G has been demonstrated to be more effective in reducing infections than the 
intermittent administration of an equivalent dose (7 - 9). The continuous infusion provides 
a longer time period above the minjmal inhibitory concentration (MIC) for the infecting 
organism The inefficacy of the intermittent therapy of most of the standard antibiotics is 
due in part to their short half-lives, which leads to a rapid elimination of the antibiotics 
from the patient's system To compensate for the short half-lives, antibiotics are often 
administered in frequent relatively large doses. 
The local administration of antibiotics into the surgical wound offers the 
opportunity of targeting only the tissues at risk of infection, concurrently mjnimizing the 
potential toxic side effects of the drug. Local administration also provides higher local 
concentrations than those obtained with systemic administration. Antibiotics have been 
directly administered to the surgical wound (10 - 12), however the rapid absorption of the 
antibiotics from the wound site reduced the duration of protection against infections. 
Local infusions (irrigation) have been used to compensate for the rapid absotption of 
antibiotics from the wound site. Local infusions have been reported to be effective in the 
prevention of wound infections (13, 14). However, this practice is cumbersome and 
requires continuous medical attention. A more convenient therapy was the locally 
implanted delivery system that provided a continuous release of a loaded antibiotic. 
Polymethylmethacrylate (PMMA) based delivery system was clinically introduced by 
Buchholz and Engelbrecht as a prophylactic measure against deep infections complicating 
total hip replacement (15). Septopal~ is the commercially available gentamicin loaded 
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PMMA copolymer (in Europe and South Africa). It is intended for the treatment of 
chronic osteomyelitis and the treatment of post-operative wound infections and soft tissue 
infections. Septopale provides sustained bactericidal gentamicin concentrations at the site 
of infection but very low systemic concentrations, offering the advantage of controlling the 
infections without the . side effects that accompany high systemic concentrations of 
gentamicin. Barton and Moil' (16) successfully used gentamicin beads for prophylaxis in 
major head and neck surgery without the use of systemic prophylactic antibiotics. They 
reported an infection rate of 18.7% with the beads, as compared to an 87% infection rate 
without prophylaxis and a 38% infection rate with parenteral cefazolin prophylaxis (16, 
17). Other reports showed encouraging results after using antibiotic beads as the only 
prophylactic used, providing the advantages of patients comfort, reduction of medical care 
and hospital expenses and the lack of major complications (17). The PMMA bone cement 
is a non-biodegradable copolymer, thus further surgical procedure is required for the 
removal of the PMMA beads from the implantation site. The removal of the beads is 
painful if performed without anesthesia, in addition to the possibility of re-infecting the 
wound during the bead removal operation (17). 
The problem of having to remove the delivery system has been avoided by the use 
of biodegradable or bioerodible material instead ofPMMA. Biodegradable materials such 
as plaster of paris, bone graft and fibrin clot were initially evaluated as carriers for 
localized delivery of antibiotics (18), but had little success due to formulation difficulties 
such as the lack of mechanical strength and the irreproducibility of the release patterns. 
Also bone graft and fibrin clot have been found to possess antigenic properties. Various 
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types of polymers have ,been developed as biocompatible and biodegradable systems to be 
used as implants for local delivery of drug, these polymers include: poly (a-esters), poly 
(aliphatic acids), polyorthoesters, polyphosphazenes, polymers based on amino acids, 
natural materials such as collagen, and polysaccharides (19). Wei et ale (20) prepared 
composites of Poly (DL-lactic acid) and dideoxykanamycin B for the treatment of bone 
infections and reported local bone drug levels exceeding the minimum inhibitory 
concentrations for the common infecting microorganisms of bones. Laurencin et ale (21) 
examined the efficacy of gentamicin-loaded polyanhydrides for the treatment of bone 
infections and reported a lower bacterial colony levels than those found in control rats and 
in rats implanted with polyanhydride alone. However, there was persistence of bacterial 
colonies. 
Polyanhydride, PMMA and Poly (DL lactic/glycolic acid) based systems are often 
developed for the treatment of bone infections, which require longer therapy than required 
in the case of postoperative wound infection (weeks and months vs. days). For wound 
infection prophylaxis, antibiotic therapy over the course of several days (3 - 5 days at the 
most) has been proven to be sufficiently effective (4). 
Glyceryl monostearate (GMS) based biodegradable implants were developed to 
provide a short term (1 - 3 days) delivery of cefazolin (see previous chapters) for the 
prevention of post-operative wound infections. Glyceryl monostearate is a natural 
monoglyceride, biologically inert, a substrate in human metabolism and synthesis of lipids 
in addition to being easy to handle, process and formulate into a delivery system Thus, 
fidfil1ing the desired characteristics of biodegradable drug delivery carriers. 
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Cefuroxime loaded GMS based devices were developed by Peri et al (22) for the 
potential use of GMS devices as a delivery system for local antibiotic therapy. Cefuroxime 
release was maintained for around three days, however there were some problems 
associated with the preparation of the devices by the melt-casting method. The melt-
casting produced devices that were difficult to disintegrate and erode. Also, the high 
temperature (75°C) used during the melt-casting process was suspected to have led to the 
degradation of the loaded antibiotic. Therefore, in this research the compression method 
was used in order to improve the disintegration and erosion characteristics of the devices 
in addition to avoiding drug degradation during the manufacturing process (see previous 
chapters). 
In this research, cefazolin, one of the most commonly used prophylactic agents, 
was incorporated into GMS based devices. Four devices were combined to provide a 
continuous delivery of cefazolin for a three day period. Each of the devices was designed 
to completely disintegrate within 3 - 5 hours after the complete release of its load of 
cefazolin. The disintegration of the GMS based devices with the aid of erosion enhancers 
was intended to facilitate the bioerosion and the subsequent bioabsorption of GMS from 
the implantation site in vivo. Previously, the GMS based devices were tested and 
evaluated in vitro (see previous chapters). In this chapter, cefazolin loaded GMS implants 
were evaluated in vivo for pharmacokinetics of the locally delivered cefazolin, efficacy and 
bioerosion. 
In vivo efficacy, pharmacokinetic and bioerosion studies of various implantable 
antibiotic devices have been performed in infected and non-infected rabbits, dogs, rodents 
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and humans (1, 16, 17, 20 - 25). Since staphylococcus aureus is the species most often 
recovered from wound infections, it has been used as the prototypic wound pathogen in 
most of the infected animal models (1), in order to evaluate the efficacy of the antibiotic-
impregnated devices in controlling wound and bone infections. Subcutaneous, muscular 
and intraperitoneal infection models have been widely used for the evaluation of the 
efficacy of antibiotics in controlling infections (1, 7, 10, 26, 27). 
Subcutaneous abscess model with Staphylococcus aureus ATCC 29213 in male 
Sprague-Dawley rat was chosen to conduct the animal study for the following reasons: 
1. The subcutaneous abscess model is widely used as a surgical infection model in the 
assessment of efficacy of antibiotic treatment (7). 
2. Staphylococcus aureus is the species most often recovered from wound infections (1). 
3. The subcutaneous abscess model in rat has been successfully used by Livingston et af 
as a clinically relevant infection model, in order to compare the efficacy of two 
methods of cefazolin administration (7). 
4. The subcutaneous abscess model is less traumatic and less stressful to the animal. 
5. The Sprague-Dawley rat is convenient to evaluate the efficacy and the 
pharmacokinetics of cefazolin released from the GMS delivery system, since this 
animal tolerates surgical trauma and long term high-dose antibiotic therapy (28). 
6. The Sprague-Dawley rat is affordable and its cost of housing is low. 
Each rat in this study received six subcutaneous injections of staphylococcus 
aureus to induce infection Each injection contained 4.5 X 107 colony forming units 
(CFU). The rats were randomly assigned to three groups: control group (no antibiotic 
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treatment), intermittent intramuscular group (intermittent 1M injections of cefazolin) or 
implant group (cefazolin released from subcutaneous implants). 
This study evaluated the cefazolin loaded GMS implants in an infected animal 
model, hence the specific aims of this study were therefore: 1) to evaluate the in vivo 
efficacy of cefazolin locally released from GMS based matrices in controlling an induced 
subcutaneous infection with staphylococcus aureus (simulation of a wound infection), 2) 
to compare the efficacy of equivalent quantities of cefazolin delivered by either, an 
intermittent intramuscular (1M) bolus injections, or a subcutaneous implants, 3) to 
evaluate the pharmacokinetics of cefazolin which was released from the GMS based 




Cefazolin sodium USP was obtained from Marsam Pharmaceuticals Inc. Cefoxitin 
USP was purchased from Merck and Co., Inc. Glyceryl monostearate (GMS) was a gift 
from Eastman Chemicals. PEG 8000 was a gift from Union Carbide. Trichloracetic acid 
was purchased from Fisher Scientific. HPLC grade acetonitrile, methanol, monobasic 
potassium phosphate, monobasic sodium phosphate and dibasic sodium phosphate were 
purchased from Curtin Matheson Scientific, Inc. Tween 80 was obtained from leI 
chemicals. Staphylococcus aureus ATCC 29213 was obtained from MUSC Microbiology 
Laboratory. Broth was obtained from Dilco Labs. Mueller Hinton n agar plates were 
obtained from BBL Labs. Ketamine HCI was obtained from Parke Davis. Xylazine HCI 
was obtained from Fermenta Veterinarian Products. Povidone-iodine was obtained from 
non-absorbable sutures was purchased from Purdue Fredrick. Normal saline for injection 
was obtained from Abbott Laboratories. Male Sprague-Dawley (275 - 325 g) rats were 
obtained from Harlan Sprague-Dawley. Cefazolin loaded GMS based devices· (coated and 
uncoated) were prepared in our laboratories (see the previous chapter). 
2.2 Instruments 
Waters Associates Model 501 pump, Waters Associates Model 710 WISP (auto-
injector), Waters Associates Model 481 LL Spectrophotometer (detector), and Waters 
Associates Mierobondapak CI8 column (3.9 mm X 30 em) were used for the HPLC assay 
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of cefazolin. Centrifuge (Fisher Microcetrifuge, Model 59A) was used to separate plasma 
from blood samples and precipitated proteins from plasma samples. Rodent restrainer 
(Plas Labs., Broom style) was used to restrain the rats during blood sampling. Dynatech® 
autodilutor was used for the serial dilutions of cefazolin solution in the micro dilution try. 
Microcaliper (General®, No. 142) was used to measure the size of abscesses. 
2.3 Methods 
2.3.1 Microbiology 
Preparation of the Staphylococcus Aureus ATCC 29213 Inoculum - The bacteria was 
obtained from MUSC Microbiology Laboratory, where staphylococcus aureus ATCC 
29213 was subcultured as follows: With a cotton swab, 5 - 6 bacterial colonies were 
removed from the staphylococcus aureus ATCC 29213 agar plate. The cotton swab was 
placed in a tube containing sterile broth and rotated several times to drop the bacteria from 
the cotton swab into the broth. The time required for staphylococcus aureus ATCC 29213 
to reach logarithmic growth phase was previously determined to be 5 hours, therefore the 
broth tube was incubated at 35°C for that length of time. A staphylococcus aureus 
inoculum suspension containing approximately 1.5 X 108 CFU/ml was prepared by 
diluting the incubated broth with sterile normal saline. This was achieved by adjusting the 
turbidity of the suspension to match the turbidity of 0.5 McFarland standard (latex particle 
suspension) measured by a spectrophotometer at 625 run (0.5 McFarland standard is 
equivalent to 1.5 X 108 CFU/ml). 
125 
Verification of the Inoculum Concentration - The McFarland assay is based on the 
measurement of the turbidity of the bacterial suspension and matching it with the turbidity 
of a latex particle suspension standard. In addition to the colony forming units, there are 
other contributors to the turbidity of the bacterial suspension such as dead bacteria cells, 
particulates, etc. The concentration of the colony forming units in the inoculum was 
verified as follows: A sample from the bacteria suspension was diluted (serial 10 fold 
dilutions) with normal saline to obtain two suspensions at concentrations, 1/105 and 1/106 
of the original bacterial concentration. Then, 20 fl.l aliquots from each suspension were 
cultured on an agar (Muellar Hinton II) plate. The plates were incubated at 35°C for 24 
hours. The colonies formed in each plate were counted and the concentration of the initial 
inoculum was calculated and verified. 
The colony forming unit concentration of Staphylococcus aureus ATCC 29213 
suspension was verified every time an inoculum was prepared. The average concentration 
of the inoculum was found to be 9.14 X 107 + 3.25 X 107 CFU/ml (n=6). 
Minimum Inhibitory Concentration (MIC) of Cefazolin for Staphylococcus Aureus 
ATCC 29213 - The MIC of cefazolin was determined using the Microdilution Broth 
technique according to the National Committee for Clinical Laboratory Standards 
(NCeLS) guidelines (29). A stock solution of cefazolin (256 Ilg/ml) in broth and a 
suspension of staphylococcus aureus ATCC 29213 (1 X 106 CFU/ml) in broth were 
prepared separately. One miJJjliter of cefazolin stock solution was dispensed into each well 
in the first row of a standard microdilution tray (8 X 12 wells). Using a Dynatech® 
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auto dilutor, 0.5 ml of the solutions in the first row were dispensed into the second row 
and mixed with 0.5 ml of sterile broth. Cefazolin solutions in the rest of the 12 rows were 
prepared in the same fashion (seria12 fold dilution). This resulted in the following series of 
cefazolin concentrations in the 12 rows: 128, 64, 32, 16, 8, 4, 2, 1, 0.5, 0.25, 0.125 and 
0.0625 flg/ml. All the wells were filled with 0.5 ml of the above mentioned staphylococcus 
aureus suspension·to achieve a final concentration of 5 X 105 CFU/ml. The microdilution 
tray was incubated for 18 hours at 35°C. The MIC was identified to be 0.5 flglml, as it 
was the lowest concentration of cefazolin that completely inhibited the growth of 
staphylococcus aureus as detected by an aided eye. This value of MIC agreed with the 
range of MIC (0.25 - 1 flg/ml of cefazolin) reported for staphylococcus aureus ATCC 
29213 by NCCLS documents (29). 
2.3.2 BPLC Assay of Cefazolin in Plasma 
Preparation of Cefazolin Standards in Plasma - Blank rat blood was centrifuged at 
3000 rpm for 5 minutes in order to separate plasma. A stock solution of cefazolin in 
plasma (CZSP) was prepared by spiking blank plasma with a concentrated aqueous 
solution of cefazolin. Aliquots of CZSP were properly diluted with blank plasma to 
prepare standards of cefazolin in plasma ranging in concentration from 2 - 60 Jlg/ml. 
Processing Samples and Standards for the HPLC Assay - Blood samples were 
collected from rats tail, allowed to clot (10 min.) then centrifuged to separate plasma. A 
100 JlI plasma was pipetted from each sample and stored in a freezer until the assay time. 
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Both plasma standards and plasma samples were treated (processed) as described below to 
prepare them for injection into the HPLC system: Forty microliters of TCA solution 
(trichloracetic acid in methanol 5 % w/v) was added to 100 fll plasma (sample or 
standard), in order to precipitate plasma proteins. The mixture was vortexed for 10 
seconds and 50 III cefoxitin solution (internal standard, 30 Ilglml) was added to the 
mixture. The resultant mixture was vortexed for 10 seconds then centrifuged at 5000 rpm 
for 10 minutes. The supernatant was separated and was ready to be injected into the 
HPLC system Three to four samples were processed at a time to avoid drug degradation. 
HPLC Analytical Conditions - Plasma extracts were analyzed for cefazolin by reversed 
phase HPLC using 3.9 mm x 30 cm Waters Microbondapak C18 column. The mobile 
phase was composed of 7 % Acetonitrile in 0.05M KH2P04• The mobile phase was 
pumped at a flow rate of 3 mVmin. Cefazolin and cefoxitin peaks were detected at 273 
nm. The retention times for cefazolin and cefoxitin were 14 and 11 minutes, respectively. 
Typical chromatographs are shown in figure 1. 
Validation of the Assay of Cefazolin in Plasma Samples 
Method Precision - Cefazolin plasma standard (9.52 flglml) was prepared and divided 
into six 100 fll aliquots. The six aliquots were processed individually as described above 
and analyzed for cefazolin concentrations by the HPLC method. 
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Linearity and Range - Cefazolin standards in plasma were prepared as described above, 
ranging in concentration from 1.87 - 57.09 Jig/mI. Standards were processed and assayed. 
The ratio of the area under the cefazolin peak to the area under the cefoxitin peak (peak 
area ratio) was plotted versus the concentration of cefazolin in the corresponding 
standard. 
Extraction Efficiency - Plasma aliquots were spiked with known amounts of cefazolin, 
processed and analyzed as described above. The concentration of cefazolin in the plasma 
aliquots was calculated using a calibration curve of cefazolin in plasma (cefazolinl cefoxitin 
peak area ratio vs. cefazolin concentration). Also the concentrations of cefazolin and 
cefoxitin were calculated using a calibration curve of cefazolin and cefoxitin in buffer 
(absolute recovery). The recovery was calculated at the following cefazolin concentrations 
in plasma: 2, 4, 10 and 40 Jig/mI. 
Stability of Cefazolin 
Stability of Cefazolin in Plasma at 4°C before Extraction: A standard solution of cefazolin 
(20 Jlg/ml) in plasma was prepared and divided into three samples. One of the samples was 
extracted and analyzed immediately, the other two samples were processed and analyzed 
the following day. 
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Stability of Cefazolin in Extracts at 4 °C: A standard of cefazolin in plasma (10 f.lg/ml) was 
extracted and a fraction of the supernatant (above the precipitated proteins) was analyzed 
immediately, while the remaining fraction was analyzed on the next day. 
2.3.3 Pilot Animal Study 
The most important objective of the pilot study was to gain a better perspective of 
the in vivo study, in order to be able to improve upon the planning and designing of the 
prospective anima] study. In addition to learning the skills required for handling the 
animals, conducting anesthesia and surgery, and obtaining blood samples. 
Four Sprague-Dawley were obtained through Department of Laboratory Animal 
Research (DLAR), MUSC. The rats were housed at DLAR facilities and allowed free 
access to food and water prior to and during the experiments. The rats were acclimated to 
the facilities for one week before the start of the experiments. Two of the rats were 
implanted (implant group) subcutaneously with cefazolin loaded devices, the other two 
received multiple intramuscular (intermittent 1M group) injections of cefazolin. Rats were 
not infected with bacteria in this study. 
Implant Group - Two Sprague-Dawley rats (300 g) were used for this experiment. Each 
r~t was anesthetized with an intramuscular injection of ketamine HC} (50 mg/kg) and 
xylazine HC} (12 mg/kg), then the dorsal fur was clipped, and the back was painted with 
povidone-iodine solution. Four subcutaneous pockets on the back of each rat were made 
using a sterile pair of surgical scissors. Four devices (one uncoated and three coated) were 
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implanted in these pockets (a device each). The four devices together were designed to 
deliver 57 mg cefazolin over a period of three days after implantation in a rat. After the 
implantation of the devices, the subcutaneous pockets were sutured with nonabsorbable 
surgical sutures. 
Blood samples were collected from one of the two rats at different time intervals 
over 3 day period. Cefazolin concentrations in plasma were determined by the HPLC 
assay. Plasma concentrations were plotted versus time. The two rats were euthanized 25 
days post-implantation and the implantation site was opened. The condition of the 
remnants of the implants and the tissues surrounding them was examined. 
Intermittent Intramuscular (1M) Group - Two Sprague-Dawley rats (300 g) were used 
for this experiment. Each rat was injected intramuscularly with two doses of cefazolin (20 
mg/kg), 8 hours apart. The rats did not receive anesthesia. Blood samples were collected 
from the rats tail at different time intervals. Cefazolin concentrations in plasma were 
determined by the HPLC assay. Cefazolin plasma concentrations were fitted to 
noncompartmental pharmacokinetic model. 
2.3.4 Experimental Design of the In Vivo Efficacy, Pharmacokinetic and 
Bioerosion Studies 
Based on the results of the pilot study, the animal study was designed and 
conducted as described below. 
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Pharmacokinetic and Efficacy Studies 
Eighteen Sprague-Dawley male rats weighing 275 - 325 mg were obtained through 
DLAR, and acclimated to the facilities for one week before the start of the experiments. 
The rats were housed at the DLAR facilities and allowed free access to food and water 
prior to and during the experiment. The rats were assigned at random to 3 groups of 6 rats 
each. Each rat in the three groups was anesthetized with an intramuscular injection of 
ketamine HCI (50 mg/kg) and xylazine HCI (12 mg/kg), then the dorsal fur was clipped, 
and the back was painted with povidone-iodine solution. Each rat received six 0.3 ml 
subcutaneous injections of Staphylococcus aureus suspension (4.5 X 107 CFU 
Staphylococcus aureus per injection), at different sites on the back (in the clipped area). 
The rats did or did not receive antibiotic treatment (before and after the inoculation) based 
on their group assignment. 
The three groups were: 
Group 1: The control group: The rats in this group did not receive any antibiotic treatment 
after the inoculations with staphylococcus aureus. No blood -samples were withdrawn 
from the rats in this group. 
Group 2: The intermittent 1M group: The rats in this group were infected and received an 
intramuscular (1M) antibiotic treatment before and after the inoculation. After the 
administration of anesthesia, the rats in this group were injected 1M with 10 mg/kg 
cefazolin every 4 hours for 68 hours (total of 18 injections, 180 mg/kg/rat). The bacterial 
inoculations (as described above) were made 20 minutes after the first cefazolin injection. 
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Blood samples were only collected after the 1st and the 14th 1M injection of cefazolin as 
described below. 
Group 3: The implant group: The rats in this group were infected and received an 
antibiotic containing implant before the inoculation. A guide template was used to help in 
assigning the implantation and the inoculation sites (Fig. 2). Four subcutaneous pockets on 
the back of each rat were made using a sterile pair of surgical scissors. Four devices were 
implanted in these pockets (a device each). The four devices together were designed to 
deliver 54 mg (equivalent to 180 mglkg) cefazolin over a period of three days after 
implantation in a rat. After the implantation of the devices, the subcutaneous pockets were 
sutured with nonabsorbable surgical sutures. Twenty minutes after the insertion of the first 
device, the bacterial injections (as described above) were made in the vicinity of the 
subcutaneous pockets. Blood samples were collected at different time intervals during the 
three day period as described below. 
Evaluation of the Pharmacokinetics of Cefazolin Delivered by either Subcutaneous 
Implants or Multiple 1M Injections - Blood samples (200 fll each) were collected from 
the tail vein after securing the animal in a comfortable restrainer. Blood sampling was 
performed by cutting 2 mm of the tail at zero time and gently squeezing the tail in order to 
collect 200 III of blood. Subsequent blood samples were obtained by gently squeezing the 
tail to induce bleeding. The blood sampling schedule for rats in the intermittent 1M group 
was: 5, 15 and 30 minutes and 1, 2 and 3 hours after the 1st and the 14th antibiotic 
injections. In the implant group the blood sampling schedule was: 0.5, 2, 5, 8, 16, 25, 32, 
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40, 48, 56, 64, 68, 72 and 76 hours after implantation. Each blood sample was allowed to 
clot (10 min.) then centrifuged at 3000 rpm for 5 minutes. Plasma (100 Ill) was separated 
and stored in the freezer until it was processed for the HPLC assay (descnl>ed above). 
Cefazolin plasma concentrations after the 1M injections were fitted to 
noncompartmental pharmacokinetic model. The pharmacokinetic parameters (absorption 
rates, elimination rates, half-life, AUC, Cmax , Cmin) were determined. Cefazolin plasma 
concentrations in the implant group were plotted versus time and the AUC, Cmax, Cmin 
were determined. Wagner-Nelson method for the assessment of the extent of drug 
absorption was used to estimate the percent of drug released from the implants at various 
time intervals (30). 
Evaluation of the In Vivo Efficacy of the Released Cefazolin from the Implanted 
Matrices in Controlling the Infection Compared to the 1M Intermittent and Control 
Groups - The rats were humanely euthanized with C02 seven days after the bacterial 
inoculation at the DLAR facilities. A dorsal incision was made to separate the skin and the 
abscesses from the underlying muscles. The encysted abscesses were dissected from the 
skin, counted, measured with a microcaliper and individually weighed. The abscesses' 
count, diameters and weights were compared among the three groups, in order to evaluate 
the efficacy of the implants in controlling the infection. 
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Bioerosion Study; Evaluation of the Bioerosion of the GMS Based Devices 
Three Sprague-Dawley rats were obtained through DLAR for this study. Each rat 
was implanted under anesthesia with four devices (as described in the implant group). The 
rats did not receive bacterial injections and were allowed free access to food and water. 
Six weeks after the implantation, the rats were euthanized and the skin in the implantation 
area was reflected away from the underlying musculature. The condition of the remnants 
of the implants and the tissues surrounding them was examined and photographed. The 
remnants of the implants were carefu.11y excised and dried. The weight loss (indication of 
bioerosion) of the implants was determined by comparing the weight of the dried remnants 
to their initial weight before implantation. 
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3. Results 
3.1 Validation of the HPLC Assay of Cefazolin in Plasma Samples 
Method Precision - The HPLC analysis of the six aliquots (9.52 Jlglml each) resulted in 
the following cefazoIinlcefoxitin peak area ratios: 1.10, 1.20, 1.26, 1.26, 1.38 and 1.18, 
with a mean of 1.23 + 0.09 (RSD of7.3%). 
Linearity and Range - An r2 of 0.99 was obtained, when the peak area ratios 
(cefazolinlcefoxitin) (Y) were plotted and regressed versus the corresponding plasma 
concentrations of cefazolin (X). The calibration curve (Fig. 3) can be described by the 
following equation: 
Y = 0.126 X - 0.080 (Eq. 1) 
The limit of detection was determined to be 0.5 f,lg/m1, however the sensitivity of 
the assay can be further increased by increasing the injection volume. 
Extraction Efficiency - When the concentration of cefazolin in the plasma aliquots was 
calculated using a calibration curve of cefazolin in plasma (cefazolinlcefoxitin peak area 
ratio vs. cefazolin concentration), the recovery was found to be: 94.02 + 11.14 % (n=2) , 
95.86 + 4.61 % (n=2), 100.87 + 7.51 % (n=8) and 99.92 + 2.32 % (n=4) for cefazolin 
concentrations of2, 4, 10 and 40 Jlg/m1, respectively. 
The concentrations of cefazolin and cefoxitin in the plasma aliquots were also 
calculated using a calibration curve of cefazolin and cefoxitin in buffer. The absolute 
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recovery ofcefazolin and cefoxitin was 115.73 + 6.21 % (n-4 at 9.8 flg/ml) and 101.32 
+ 2.41 % (n-4 at of 8.4 flg/ml), respectively. These high recovery values can be attributed 
to the contraction of the sample volume as the plasma proteins were precipitated from 
plasma. When corrected for volume change, the absolute recovery of cefazolin and 
cefoxitin was found to be 92.58 + 4.98 % and 81.06 + 1.94 %, respectively. 
Stability of Cefazolin 
Stability of Cefazolin in Plasma at 4°C before Extraction: The peak area ratio for the 
sample (20 Jlg/ml cefazolin) that was extracted immediately was 2.22. The two samples 
which were stored at 4°C and extracted 24 hours later yielded peak area ratios of2.09 and 
2.14 corresponding to 94 % and 96 % of the peak area ratio of the sample assayed on the 
previous day. The RSD (3.05%) of these three samples was within the RSD (1 - 7 %) 
obtained for samples analyzed on the same day. This indicates the insignificant degradation 
of cefazolin in plasma when stored at 4°C for 24 hours. 
Stability of Cefazolin in Extracts at 4°C: The fraction of the extract (10 Jlg/ml cefazolin) 
that was assayed immediately yielded a peak area ratio of 1.18. This is similar to the ratio 
of 1.19 obtained from the remaining fraction which was stored at 4°C for 24 hours. This 
indicated that cefazolin was stable in the extract when kept at 4°C for 24 hours. 
Although, cefazolin was found to be stable in both plasma and the plasma extract 
for 24 hours at 4°C, plasma samples were immediately frozen and stored at -10°C after 
obtaining them from the rats and only 3 - 5 plasma samples were extracted or processed at 
137 
the same time in order to prevent any degradation of cefazolin before, during and after the 
processing and analysis of the samples. 
3.2 Pilot Study 
3.2.1 Implant Group 
Figure 4 shows that the cefazolin delivered form the implants maintained plasma 
concentrations well above the MIC for staphylococcus aureus (0.5 J.lg/ml) for a three day 
period. The plasma profile shows that after the initial relatively high plasma concentrations 
(27 J.lg/ml) for the first 8 hours, the plasma levels were maintained between 5 - 10 flg/ml 
for the rest of the 70 hours. 
Twenty five days post implantation, two out of the four implanted matrices 
disappeared completely in one rat, whereas only one implant disappeared in the other rat. 
The remnants of the rest of the matrices were in a pasty form. No visible irritation was 
obselVed in the tissues surrounding the implants. The lack of any visible irritation around 
the implants, in addition to the disappearance of some of the implants and the physical 
condition (pasty form) of the remnants of the other implants are good indications of the 
biocompatibility and the bioerodibility of our GMS based delivery system 
3.2.2 Intermittent Intramuscular (1M) Group 
The plasma concentration time profile of cefazolin in this group appear in figure 5. 
The plasma concentrations after the two doses were fitted simultaneously to the following 
equations: 
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tl = unit (t) * t (Eq.2) 




where C is plasma concentration of cefazolin at time t, ke is the apparent first-order 
elimination rate constant, ka is the apparent first-order absorption rate constant, Ci and Cj 
are the Y axis intercepts, PI is the plasma concentration after the first injection at time tl 
and P2 is the plasma concentration after the second injection at time t2. 
The elimination and absorption rate constants were found to be 1.43 + 0.34 hr-1 
and 10.29 + 3.61 hr-t, respectively. These values are similar to those obtained by fitting the 
plasma concentrations reported by Intoccia et af (31) (ke = 1.33 hr-1 and ka = 10.27 hr-1 ) 
after a single 1M injection of cefazolin 20 mg/kg to Sprague-Dawley rats (n=30). Plasma 
concentrations after an 1M injection of cefazolin (20mg/kg), ranged between 105 J-lg/ml 
and 0.5 f.lg/ml (calculated, below assay detection), at 15 minutes and 4 hours, respectively. 
3.2.3 Recommendation Based on the Pilot Study 
The combination of the four GMS based matrices was successful in delivering 
cefazolin for three days after the subcutaneous implantation in rat. The initially (first 8 
hours) high plasma concentrations (27 Jlg/ml) of cefazolin, were a result of the release 
from the uncoated device. The amount of cefazolin released in the initial 8 hours was 
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unnecessarily high and resulted in plasma concentrations that are 54 times the MIC. Based 
on the cefazolin release kinetic studies, the reduction of cefazolin load in the uncoated 
matrix would reduce the amount of cefazolin delivered during the initial period after 
implantation. The reduction in the amount of cefazolin delivered in the initial period is 
aimed at obtaining a more uniform in vivo release profile, where cefazolin plasma 
concentrations range between 5 and 10 IJglml. Therefore, the load of cefazolin in the 
uncoated device was recommended to be reduced in the devices used for the prospective 
study. 
The 1M administration of cefazolin every 8 hour had· led to time intervals (nearly 4 
hours), during which no significant concentration of cefazolin were present in the plasma. 
This was due to the short half-life of cefazolin (30 minutes), which had resulted in 
reducing the cefazolin plasma concentration to insignificant level (below MIC) after 4 
hours (eight t1l2) of administration. Therefore, the dosing interval of cefazolin was 
recommended to be reduced to 4 hours in the prospective study, while keeping the total 
dose of cefazolin constant at 180 mglkg over three day period. 
3.3 The In Vivo Efficacy, Pharmacokinetic and Bioerosion Studies 
3.3.1 Evaluation of the Infection Model 
Most (21/36) of the inoculation of 4.5 X 107 CFU of staphylococcus aureus 
ATCC 29213 in the control rats resulted in the formation of discrete abscesses (table I). 
The subculturing of the abscesses resulted in the growth of staphylococcus aureus ATCC 
29213 verifying that the inoculation was the reason for the development of the abscesses. 
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The formation of abscesses in all the rats of the control group signifies the ability of the 
staphylococcus aureus for developing subcutaneous infections in the this rat model 
Therefore, the ability of an antibiotic therapy for eradicating and inhIoiting the growth of 
the bacterial infection can be tested and evaluated using this infection model. The bacterial 
inoculation was chosen to be large (4.5 X 107 CFU), in order to be able to evaluate the 
efficacy of the antibiotic therapy of the two treatment groups (Intermittent 1M injections 
and Implants). The examination of the inoculation sites for abscesses was conducted seven 
days after the inoculations, which corresponds to four days after the termination of the 
antibiotic therapy in the treatment groups. This time period (four days) was intended to 
allow the bacteria that smvived the therapy (if any) to re-establish the infection and form 
abscesses so we can distinguish between the bactericidal and the bacteriostatic efficacy of 
the antibiotic treatment. 
3.3.2 Efficacy of the Released Cefazolin from the Implanted Matrices in 
Controlling the Infection Compared to the 1M Intermittent and Control 
Groups 
If the subcutaneously injected staphylococcus aureus was not eradicated (killed) 
by the antibiotic therapy, it will result in the formation of abscesses at the inoculation sites. 
The size, weight and number of the abscesses reflect the severity of the infection and the 
failure of the antibiotic therapy in controlling and containing the infection. Therefore, the 
number of the abscesses formed was used as an indicator of the efficacy of the treatments. 
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One week after the inoculation, the six rats in the control group (no antibiotic 
treatment) had collectively developed 21 abscesses out of the total 36 bacterial injections 
(6 injections per rat). The number of the developed abscesses varied from rat to rat. The 
average weight and diameter of the encysted abscesses were 32.47 + 28.20 mg and 2.67 + 
1.28 mm (n= 21), respectively. In the implant group, none of the 36 inoculations resulted 
in the formation of abscesses, signifying the total eradication of the staphylococcus aureus 
infection due to the sustained localized delivery of cefazolin for the duration of three days. 
The intermittent 1M administration of cefazolin resulted in the eradication of infection in 
five out of the six rats, the sixth rat had only one small abscess (8 mg, 0.5 mm). 
Statistically, there was no significant difference between the efficacy of the two treatments 
(intermittent 1M: injections and implants). The efficacy of the treatments was compared to 
the control group by comparing the number of abscesses formed in each treatment group 
to those in the control group as seen in table n. Based on this comparison the efficacy of 
cefazolin delivered from the implants and administered as intermittent 1M injections (every 
four hours) were 100 % and 95 %, respectively. 
3.3.3 Pharmacokinetics of Cefazolin Delivered by either Subcutaneous Implants or 
Multiple 1M Injections 
Pharmacokinetics of Cefazolin Delivered by the Subcutaneous Implants - Cefazolin 
was continuously delivered from the implants for three days (fig. 6). Cefazolin plasma 
concentrations were maintained at 17.5 Jlg/ml for the first two hours. Later, cefazolin 
concentrations started to decrease and then nearly plateaued between the 8th and the 32nd 
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hour, during which, the plasma concentrations of cefazolin ranged between 5.5 and 7.5 
flglmI. AfteIWards, the plasma concentrations increased to range between 9 and 14.5 
f.1g/ml, during the time period between the 40th and 64th hour, as the release of cefazolin 
was occurring from the coated implants. Cefazolin release from the first coated implant is 
expected to have started between the 25th and the 30th. After the 64th hour, the plasma 
concentrations started to decrease as cefazolin release from the implants approached 
termination (average of 6 rats). The overall plasma concentrations ranged between (Cmin) 
1.75 J.1g/ml at 76 hours and (emax) 17.5 f.1g1ml at 30 minutes during the 76 hours, 
averaging 9.3 ± 4.9 JIg/mI. The area under the curve (AUC) was calculated to be 703.67 + 
131.17 J.1g*hr/ml (n=6). 
Pharmacokinetics of Cefazolin Administered as Multiple 1M Injections - The plasma 
concentrations of cefazolin in this group fluctuated tremendously (fig. 7). After the first 
Il\1 injection of 10 mglkg cefazolin which was administered under anesthesia, the plasma 
concentrations ranged between 34 J.1g/ml (Cmax) at 15 minutes and 6 f.1g1ml (Cmin) at 4 
hours (n=6). While the plasma concentrations ranged between 44 J.1g1m1(Cmax) and 0.40 
f.1g/ml (Cmin), IS minutes and 4 hours after the 14th ( steady state) 1M injection of 10 
mglkg cefazolin, respectively (n=6). 
Cefazolin plasma profiles after the 1 st and the 14th dose were fitted independently 
to the following noncompartmental pharmacokinetic model: 
C=Cie- ket -Cie-~t (Eq.7) 
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The absorption rate constants were 15.80 + 9.17 hr- l and 11.88 + 7.35 hr-1 after the 
first and the 14th dose, respectively (n-6). The elimination rate constants were 0.46 + 
0.13 hr- l and 1.27 + 0.16 hr- I after the first and the 14th dose, respectively (n=6). The 
elimination rate constant (ke) of cefazolin was slower after the first dose compared to that 
after the 14th dose. The reduction in the elimination rate constant under anesthesia can be 
attributed to the effect of the anesthetic agents (ketamine/xylazine) on the blood flow (32). 
The administration of anesthesia reduces the blood flow through the kidneys and since 96 
% of cefazolin is renally eliminated in Sprague-Dawley rats, therefore the administration of 
the anesthetic agents had resulted in the overall reduction in cefazolin elimination (31). 
Cefazolin t1l2 is about 30 minutes, thus steady state plasma concentrations were 
achieved in 2 hours (4 tll2). Therefore, the pharmacokinetic parameters obtained from the 
14th dose were employed in simulating the plasma profile (fig. 8) for all the doses except 
for the first dose (assuming no anesthesia effect on the 2nd dose). The AUC for the whole 
profile (18 doses) was calculated to be 783.96 + 122.38 flg*hr/ml (n=6). 
3.3.4 The In Vivo Release and Absorption of Cefazolin from the Implants 
The extent of absorption of cefazolin from the subcutaneous is expected to be 
identical to that occurring from the muscular tissues, and since the AUe of cefazolin 
delivered by the implants during the three day period was not significantly different (p= 
0.3) from the AUC of identical dose administered as multiple 1M injections. Therefore, all 
of the cefazolin load in the implants was accounted for and we can conclude that the entire 
load of cefazolin was released intact during the three day period. 
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The Wagner-Nelson method is usually used to estimate the percent of drug 
absorbed rather than the percent released. The absorption rate of cefazolin from the 
implantation site is expected to have been much faster than the release rate from the 
implants (based on 1M and in vitro release data). Therefore, the rate limiting step for the 
appearance of cefazolin in plasma is the release rate of cefazolin from the implants rather 
than the absorption rate. Thus, the amount of drug absorbed is proportional to the amount 
of drug released. Therefore, Wagner-Nelson method was used to estimated the percent of 
cefazolin released from the implants at various time intervals. Figure 9 shows the in vivo 
release of cefazolin from the GMS based implants compared to that in vitro. The in vivo 
release of cefazolin from the combination of the four devices was nearly linear. The in vivo 
release profile paralleled the in vitro release profile for the first 20 hours. However, after 
32 hours the in vivo release profile from the coated devices had a smaller slope than that 
in vitro, signifying a slower release rate in vivo from the coated devices. In vitro, the 
coating layer swelled and broke away from the core, exposing the core to the release 
medium. In contrast, in vivo, the devices were confined at the implantation site and the 
coating layer could not break away from the core and the release of drug had to be 
through the coating layer. This led to a slower release of cefazolin in vivo than in vitro 
from the coated devices. Overall, there was an excellent correlation (0.98) between the in 
vivo and the in vitro release of cefazolin from the GMS based implants. 
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3.3.5 Bioerosion of the GMS Based Implants 
None of the six rats in the implant group (efficacy and pharmacokinetic study) died 
during the entire experiment. Even though, the rats were inoculated with staphylococcus 
aureus, they were heahhy and the incisions made to insert the implants were completely 
healed within the first three days of implantation. The lack of inflammation at the 
implantation site even at the early stages, signifies the biocompatibility of the GMS based 
implants and shows that the implants were not rejected by the rats' immune system 
During the six week period, the three rats employed in the erosion study were 
healthy for the entire duration of the study. The incisions made to insert the implants were 
completely healed within the first three days of implantation. Upon the opening of the 
implantation site (six weeks post-implantation), the implants' remnants were in a pasty 
form and no visible irritation nor significant fibrosis was found around them This signifies 
the biocompatibility of the GMS based implants. One of the four implants completely 
disappeared in rat # 2 as well as in rat # 3. The remaining implants had lost significant 
weight. The weight loss ranged from 20 - 1 00% (fig. 10). The disappearing of some of the 
implants in addition to the weight loss in the remaining are a good indication of the 
bioerosion and the bioabsorption of the GMS based implants from the implantation site. 
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4. Discussion 
The systemic administration of antibiotics over the course of several days (5 days 
at the most) has been reported to be effective in reducing wound infections after 
contaminated and clean-contaminated surgeries ( 4 ), when care is given to provide 
effective tissue concentrations of the antibiotic for an adequate period of time. The 
application of antibiotics directly to the surgical wound site targeted the tissues at that site 
(risk of infection) while minimizing the systemic exposure to unnecessarily high antibiotic 
levels (10 - 12). The drawback of the local treatment is the rapid absorption of the 
antibiotics from the application site, which limits the duration of the effective 
concentrations at the wound for a short time, thus rendering this treatment ineffective. The 
use of a sustained delivery system would be advantageous in maintaining effective local 
antibiotic concentrations for an adequate duration in order to overcome the drawback of 
the direct application of antibiotics. The local sustained delivery of antibiotics would also 
be more effective, less toxic and more convenient to the patient than the systemic 
(parenteral) adminjstration. 
Many degradable and non-degradable materials such as polyanhydride (21), and 
PMMA (16, 23), respectively, were investigated for the use as carriers for localized 
sustained delivery of antibiotics for the treatment of chronic osteomyelitis and post-
operative wound infections. Most of the research concentrated on the treatment of bone 
infections ( osteomyelitis), where the delivery systems were designed to sustain the release 
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of antibiotics for a longer time than needed for post-operative wound infection prophylaxis 
(weeks and months vs. 1 - 5 days). 
This research designed and developed a bioerodible sustained delivery system 
based on glyceryl mono stearate (GMS) for the short term local delivery of cefazolin (the 
most commonly used prophylactic agent) for the prevention of post-operative wound 
infections. The cefazolin loaded devices are intended to be implanted in the surgical 
wound before the wound closure. The devices are designed to slowly release cefazolin 
over a period of three days in the locality of the wound, where the infection is expected to 
occur. The devices are intended for providing high concentrations of cefazolin at the 
wound area and reducing the unnecessary systemic exposure. The proper use of these 
devices as a prophylactic measure will obviate the use of a systemic post-operative 
prophylactic. 
The efficacy of the cefazolin delivered by the GMS based devices was evaluated in 
rat model subcutaneously infected with staphylococcus aureus (simulation of a wound 
infection). The devices were subcutaneously implanted in the vicinity of the bacterial 
inoculations. The local continuous release of cefazolin from the GMS delivery system 
successfully controlled and prevented the development of the bacterial inoculations into 
abscesses. No abscesses were formed in the rats of the implant group (100% eradication 
of infection). Meanwhile, in the intermittent 1M group, only one out of the 36 inoculations 
resulted in the formation of an abscess. There was no significant difference between the 
efficacy of the two treatments (implants and intermittent injections) in controlling the 
infection. This finding is comparable with other studies (7 - 9) which have not sho\W 
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significant superiority in efficacy of the continuous delivery of antibiotics over the 
intermittent administration of equal doses, when the antibiotics are administered in high 
enough doses. Vogelman et al (33), demonstrated that the maximum bactericidal efficacy 
of cefazolin against staphylococcus aureus in a thigh-infection model occurred when the 
drug concentrations exceeded the MIC for 55% of the dosing interval. Maintaining 
concentrations above MIC for more than 55% of the dosing intelVal had no further 
beneficial effect. In this study, the intermittent injections of cefazolin were administered in 
frequent doses (10 mglkg q. 4 hours). This practice is expected to have provided cefazolin 
to the inoculation site (subcutaneous tissues) at concentrations above the MIC for a period 
longer than 55% of the dosing interval (4 hours). Therefore, the efficacy results did not 
support the superiority of the local delivery of cefazolin over the intermittent injections. In 
order to prove the superiority of the local continuous delivery of cefazolin, studies should 
be designed to compare efficacy of smaller doses of cefazolin. Theoretically, the local 
delivery of cefazolin from the implants provides higher concentrations of cefazolin at the 
implantation area where it is most needed, than those provided by the systemic 
administration of the same dose. 
It is expected that the dose required to be delivered systemically is several folds 
higher than that required by the local delivery of an antibiotic in order to achieve the same 
extent of efficacy. As seen in the multicompartment model in figure 11, after the systemic 
administration of the antibiotic, it will be distributed by blood from the central 
compartment into the peripheral compartments including the infection site. This reduces 
the antibiotic concentration before it reaches the infection site where it is needed the most. 
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In contrast, when the antibiotic is administered locally (into the infection site 
compartment), it provides higher transient concentrations at the local site than in the other 
compartments. Therefore, smaller doses of the antibiotic are required when the antibiotic 
is delivered locally in order to achieve the same concentrations at the site of infection and 
consequently to achieve the same efficacy of systemic adminjstration. The local 
administration of antibiotics is guaranteed to provide effective concentrations at local 
tissues. In contrast, the systemic adminjstration could fail to provide effective 
concentrations to the tissues, especially in the case of necrosis and when the blood supply 
to these tissues is compromised. 
The GMS based implants maintained cefazolin plasma concentrations between 5.5 
- 17.5 Ilglml for 68 hours with very little fluctuation, while the intermittent 1M injections 
of cefazolin resulted in a highly fluctuated plasma profile, in which the plasma 
concentrations at steady state ranged between 0.40 - 44 f.1g1ml every 4 hours (fig. 12) (3-
fold vs. 1 IO-fold fluctuation). Due to the short half-life of cefazolin in rat (30 minutes), the 
1M administration of cefazolin was required every 4 hours in order to maintain a 
continuous presence of cefazolin in the plasma. Eighteen 1M injections (injection every 4 
hours) of cefazolin were required in order to provide the same amount of cefazolin 
delivered by the implants over a period of three days. In surgical settings, the antibiotic 
delivery system is to be implanted into the surgical wound at the time .of surgery, i.e. one 
time administration. The implants, thus release the antibiotic for the duration of the 
prophylactic therapy without the need for the inconvenient repeated systemic injections. In 
addition to the patient's convenience, the use of implants will also reduce the patient's 
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care costs by reducing the cost for administering the injections and the possible earlier 
patient mobilization and the reduction in hospital stay. 
With the local sustained delivery of an antibiotic, smaller doses of the antibiotic are 
required to be used for this prophylactic therapy to be effective. The sustained delivery of 
these smaller doses will result in a less fluctuating release profile (mimicking an infusion) 
compared to bolus delivery of identical doses of the antibiotic. Thus, the overall systemic 
exposure is reduced and the tissue and plasma concentration fluctuations (peak and valley) 
are eliminated. The systemic prophylactic therapy requires high plasma concentrations in 
order to secure sufficiently adequate concentrations of the antibiotic at the site of surgical 
wound, Le. the systemic administration is effectively over-dosing. The systemic exposure 
to high concentrations of a drug could lead to serious side effects and even toxicity. Side 
effects and systemic toxicity of aminoglycosides (gentamicin and tobramycin) are more 
pronounced and more drastic than those of cephalosporines (cefazolin and cefuroxime), 
because the therapeutic windows of the aminoglycosides are much narrower and their 
MICs are closer to the toxic concentration compared to cephalosporines (5). The use of 
the GMS based devices for the local delivery of an aminoglycoside such as gentamicin 
would be advantageous in reducing the systemic exposure to unnecessarily high 
concentrations of gentamicin thus, protecting against nephrotoxicity and ototoxicity with 
an improvement in efficacy. 
In the literature (18, 20, 24, 34), the release rate of highly water soluble antibiotics 
(including cefazolin) from PMMA, bone grafts, demineralized bone matrix, polyanhydrides 
and poly(D,L-lactide) has been described to decrease as time progressed. The drug release 
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is initially rapid, followed by a much slower release for an extended period of time. In 
most cases, after the initial period, the amount released provides antibiotic concentrations 
below the MIC. Thus, the release of this low amounts is ineffective against the infection 
and will potentially lead to the development of resistant strains of bacteria. Therefore, a 
constant (zero order) release rate of adequate amounts of antibiotics is needed in order to 
overcome the disadvantages associated with the other release patterns (square root of time 
and first order release). In this study, the release of cefazolin from the combination of the 
four GMS based implants was maintained for three days. The release rate of cefazolin was 
nearly zero order during the entire 3 day period (fig. 10). Thus, mimicking a continuous 
zero order infusion and avoiding the disadvantages associated with a release rate that 
decreases with time. 
Cefazolin is liable to degradation (hydrolysis) especially at body temperatures. It 
was found in vitro, that cefazolin in the OMS based devices did not degrade even though 
it was subject to 37°C for nearly three days. The GMS matrix protected the degradation of 
cefazolin by preventing the contact between the release medium and the cefazolin that was 
yet to be released. In vivo, it was found that the AUC of the plasma profile of cefazolin 
released from the implants was not significantly different from that of cefazolin 
administered by multiple 1M injections. Assuming the same extent of cefazolin absorption 
from the intramuscular and the subcutaneous administration site, one can deduce that 
cefazolin inside the GMS matrix was protected from degradation and all the loaded 
cefazolin was released intact from the implants over the three day period confirming the in 
vitro results concerning the stability of cefazolin in the OMS based devices. 
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Natural glycerides, such as mono-, di-, and tri-palmitate have been investigated 
for the development of implantable, biodegradable drug delivery systems for the controlled 
release of narcotic antagonists such as naltrexone (35). The biodegradability of glycerides 
pellets was investigated in rabbit. Almost 80% of the 29 dipalmitate pellets implanted were 
obsetved to disappear completely from the intramusclar sites within 3 months. The 
biodegradation of the glyceride based matrix depended on its composition. The 
replacement of the dipalmitin with monopalmitin increased the rate of biodegradation of 
the glyceride implants. No appreciable tissue reactions were detected after implantation of 
either dipalmitin or tripalmitin in rat, rabbit, or pig at the sites of intramusclar, 
subcutaneous or intraperitoneal administration. No significant amount offibrosis was seen 
around the pellets for as long as 1 year and no gross indications of toxic effects were 
evident (35). In this study, glyceryl monostearate (GMS) was used for the preparation of 
the sustained delivery matrix. The bioerosion and biodegradation of GMS is expected to 
be slower than that of the palmitate glycerides due to the longer chain fatty acid (palmitic 
(C}6) vs. stearic acid (C}s». Therefore, biocompatible erosion enhancers were 
incorporated into the GMS matrix in order to increase the in vivo erosion and absorption 
of the GMS devices from the implantation site. The erosion enhancers increased the rate 
of disintegration of the mat~ creating larger surface area for the biodegradation and 
bioabsotption to occur from 
In this study, no gross adverse effects were obseIVed and all the rats were alive and 
healthy for the entire duration of the study (six weeks). The surgical wounds created for 
implanting the devices were healed with out an indication of inflammation in the 
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implantation site. After the six weeks of implantation, 2 out of the 12 implants completely 
disappeared. The rest of the implants lost significant weight (20 - 80% weight loss) due to 
the biodegradation and bioabsorption processes. Upon opening the implantation site, no 
visible irritation was found in the subcutaneous tissues around the implants and no 
appreciable tissue reactions were observed. The well being of the rats and the absence of a 
visible irritation in the subcutaneous tissues as well as the erosion of the implants are 
good indicators of the biocompatibility and the bioerodibility of our GMS based implants. 
More studies are needed on the cellular level to definitely determine the safety of GMS 
implants. 
The plasma concentrations of cefazolin after the 1M administration of 10 mg/kg 
cefazolin were fitted using a single compartment model. The elimination (kc) and 
absorption (ka) rate constants were found to be 1.27 ± 0.16 hr· I and 11.88 ± 7.35 hr- I , 
respectively (n=6) when cefazolin was administered without anesthesia. This coincides 
with what has been reported by Intoccia et al (31) (Ice = 1.33 hr- I and ka = 10.27 hr- I ) after 
a single 1M injection of cefazolin 20 mglkg to Sprague-Dawley rats (n=30). However, the 
elimination (ke) and absorption (ka) rate constants were 0.46 ± 0.13 hr -1 and 15.80 ± 9. 17 
hr- I , respectively (n=6) when cefazolin was administered with anesthesia. The elimination 
rate constant of cefazolin was significantly lower when administered under anesthesia 
(0.46 ± 0.13 hr- I vs. 1.27 ± 0.16 hr-1) (p= 2.04 X 10- 6). The combination ofketamine and 
xylazine for the anesthesia has been reported to reduce the blood pressure of rodents (32). 
The reduction in blood pressure is accompanied by a reduction in blood flow, and since 96 
0/0 of cefazolin is eliminated renally, the reduction in blood flow through the kidneys had 
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resulted in the overall reduction of the elimination rate of cefazolin (31). The AUe with 
anesthesia (69.75 ± 14.04 flg*hr/ml) was significantly higher than that without anesthesia 
(44.70 ± 6.76 flg*hr/ml) (p = 0.002) and the relative bioavailability of cefazolin with 
anesthesia was 1.56 times the bioavailability of cefazolin without anesthesia, indicating a 
slower clearance under anesthesia. The effect of anesthesia can also be seen on the plasma 
profiles of the rats in the implant group, in which the elimination during the initial 4 - 6 
hours was expected to be reduced under the influence of the anesthetic agents (31). The 
reduction in the elimination rate during the initial 6 hours is expected to be an important 
factor in addition to the initial burst release from the implants, in producing the relatively 
higher plasma concentrations compared to the following time period (17.5 vs. 5.5 flg/ml). 
This study had demonstrated the efficacy of the local delivery of cefazolin by the 
GMS based implants in eradicating staphylococcus aureus infection. It also demonstrated 
the ability of the designed combination of implants to deliver cefazolin for a three day 
period at a constant delivery rate. The study exhibited excellent indications about the 
safety, biocompatibility and bioerosion of the implants. Using this GMS delivery syste~ 
the duration of the antibiotic therapy in addition to the dose can be tailored to fit the 
requirement of the surgeon. The duration of antibiotic delivery is controlled by the design 
and the composition of the GMS based implants (see previous chapter). With further 
development and clinical testing, the GMS based delivery system can be used by surgeons 
as a useful and effective prophylactic measure against post-operative wound infections. 
More studies should be conducted to determine the minimum dose of cefazolin 
that is effective as a locally delivered prophylactic antibiotic, in order to reduce the dosing 
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of the antibiotic. Other anttoiotics with serious side effects such as gentamicin that can 
cause ototoxicity and nephrotoxicity, can be delivered more safely and effectively by the 
GMS based implants. This will be advantageous for providing better localized protection 
and minimizing the systemic exposure to gentamicin. Although, the initial data gathered by 
this study do not support the presence of major toxicity problems, gross and cellular 
toxicological studies of the GMS based implants should be conducted thoroughly before 
testing this delivery system in humans. 
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5. Conclusions 
Rat infection model was used to simulate a post-operative wound infection, in 
order to evaluate the efficacy of the cefazolin loaded GMS implants as a prophylactic 
measure. The local continuous release of cefazolin from the GMS delivery system 
successfully eradicated the staphylococcus aureus induced infection in all the rats. There 
was no significant difference in efficacy between the implant and the intermittent 1M 
group. Theoretically, the local delivery of cefazolin from the implants provides higher 
concentrations of cefazolin at the implantation area than the systemic administration of the 
same dose. Based on that, it is expected that lower dose of cefazolin is required when it is 
administered locally than required by a systemic administration. Therefore, the superiority 
in efficacy of the local continuous delivery of cefazolin can be proven by comparing the 
admjnjstration of smaller doses of cefazolin. 
This research successfully designed GMS based implants that delivered cefazolin in 
vivo (rat model) for a three day period. The release rate of cefazolin was nearly zero order 
which is preferred for a delivery system and the entire load of cefazolin was released in the 
three day period. Cefazolin plasma levels in the implant group were maintained between 
5.5 - 17.5 f.lg/ml for nearly three days. On the other hand, the intermittent 1M 
administration of cefazolin resulted in a highly fluctuated plasma profile, in which the 
plasma concentrations at steady state ranged between 0.40 - 44 f.lglml every 4 hours. 
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The well being of the rats and the absence of a visible irritation in the subcutaneous 
tissues as well as the erosion of the implants (some even disappeared completely) are 
good indicators of the biocompatibility and the bioerodibility of our GMS based implants. 
Overall, the research was successful in designing and developing an effective, 
biodegradable, bioerodible delivery system based on GMS for the local delivery of 
antibiotics for the prevention of post-operative wound infection. 
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Table I. Number, size and weight of the abscesses formed in the rats in the control groups, 
one week after the subcutaneous inoculation with staphylococcus aureus. 
Rat No. Number of Abscesses Formed! Diameter (mm) Weight (mg) 
Number of Inoculations Mean± SD Mean± SD 
1 4/6 2.88 ± 0.75 19.25 ± 5.19 
2 4/6 2.00 ± 1.22 13.25 ± 9.64 
3 5/6 3.00 ± 1.58 44.00 ± 28.58 
4 2/6 3.25 ± 3.18 68.00 ± 80.61 
5 4/6 2.75 ± 0.86 35.25 ± 10.44 
6 2/6 2.00 ± 0.00 27.50 ± 0.71 
Total 21/36 2.67 ± 1.28 32.47 ± 28.20 
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Table ll. Efficacy of the local delivery of cefazolin by GMS based implants. The table 
compares the efficacy in the three groups by comparing the number, size and weight of the 
formed abscesses at the inoculation site. 
Group Number of Efficacy Diameter (mm) Weight (mg) 
(Number of rats) Abscesses Compared to Mean+SD Mean +SD 
Formed Control 
Control (6) 21/36 2.67 + 1.28 32.47 + 28.20 
Intermittent 1M (6) 1/36 95% 0.5 8 
Implant (6) 0/36 100% 
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Figure 1. Typical chromatograms of cefazolin after extraction from plasma samples. Cefazolin and cefoxitin peaks appear at 14 and 11 
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Figure 2. Schematic of the guide template used to assign the locations of the implantation of the OMS devices and the bacterial 
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Figure 7. Cefazolin plasma profiles after the administration of the 1 st (under anesthesia) and the 14th (no anesthesia) dose of 
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Figure 8. Simulation of plasma profile of cefazolin after multiple i.m. injections of 10 mg/kg cefazolin every 4 hours in Sprague-
Dawley rat, using pharmacokinetic parameters obtained from the 1st dose for simulating the 1 st dose and those obtained fonn the 14th 




















o 10 20 30 40 50 60 70 80 
Time (hour) 
Figure 9. In vivo release of cefazolin from OMS based devices implanted subcutaneously in Sprague-Dawley rats (n=6) compared to 
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Figure 10. Bioerosion of the four OMS based implants, as measured by the weight loss of the implants, six weeks post subcutaneous 
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Figure 11. Schematic diagram illustrating the advantage of the local administration of the 
antibiotic directly to the infection site. Under conditions, in which the infection site is well 
supplied with blood, both the systemic and local treatment would be effective, however a 
lower dose would be required with the local delivery. Under conditions, in which the 
blood supply to the infection site is compromised (necrosis), the local delivery would be 
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Figure 12. Comparison of plasma profiles of cefazolin delivered by multiple Lm. injections and OMS implants (n=6). 
